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Amyotrophic Lateral SclerosisAgeing of the neuromuscular system in elderhood ingravescently contributes to slowness, weakness, falling and
death, often accompanied by numbness and pain. This article is to put in perspective examples from a half-
century of personal and team neuromuscular histochemical–pathological and clinical–pathological research, in-
cluding a number of lucky and instructive accomplishments identifying new treatments and new diseases. A
major focus currently is on some important, still enigmatic, aspects of the ageing neuromuscular system. It is
also includes some of the newest references of others on various closely-related aspects of this ageing system.
The article may help guide others in their molecular-based endeavors to identify paths leading to discovering
new treatments and new pathogenic aspects. These are certainly needed – our ageing and unsteady constituents
are steadily increasing. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology andMo-
lecular Pathogenesis.
© 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
1.1. Ageing is ubiquitous – everything ages, in the 4th dimension
100–400 billion cosmic stars, including our sun and its solar system,
are in ourMilkyWay galaxy, soaring through space. The cosmic stars are
predestined to age, from young hot and blue hydrogen-burners to red-
giants burning heavier elements to their predestined extinction in a
massive explosion of a supernova releasing a huge amount of energy,
or becoming a powerful black hole, at age about 50 million years (our
sun has about 10 million years to go before stellar death). Movie stars
age, and the molecules of the media on which they are eternalized
age. Mountains age and crumble, beaches erode. Machines age to inefﬁ-
ciency. Plumbingpipes and arteries small and large age, corrode and cal-
cify to uselessness of narrowed and dangerous blocking or breaking.
Philosophies and governments, and those governing and governed,
age. All living creatures, animals and plants, cells and dinosaurs age,
having an innate and unalterably programmed drive to live and repro-
duce their species, but in an optimal manner for only a limited time,
until the decline of ageing becomes overwhelming and fatal. In humans,uscular Diseases: Pathology and
1 213 975 9950; fax: +1 213
. This is an open access article under“ageing” seems to begin about age 20–30, although some consider it
dates from birth, or even conception.
1.2. Big Bang
With the Big Bang, 13.82 billion,± a few, years ago our cosmos had a
dramatic birth (conventional wisdom) – our entire cosmic universe ex-
panded, in a trillionth of a trillionth of a second, from an inﬁnitely-small
(smaller than a proton), inﬁnitely-dense, and inﬁnitely-hot speck of
“singularity” mass (which appeared out of nowhere), to become of
seemingly-limitless size and rather ﬂat, possibly joiningwith other uni-
verses in a putative “multiverse”. Prior to that singularity, nothing
existed, not space, matter, energy or time – nothing [1]. Allegedly, micro-
waves and gravitational waves emanating from a period “soon” after
that birth are now reaching our radiotelescope detectors. (A new con-
cept on our universe's birth alternatively suggests it actually “emerged
as a consequence of the formation of a black hole in a higher dimension-
al universe” [2]. Regardless, our universe is probably still expanding, as
evidenced by galaxies ﬂeeting by the super-telescopic windows on our
universe. But whether our expanding universe is actually beginning to
show its age by slowing, it's a bit too soon to tell.
1.3. An anti-ageing goal?
Do physicians and scientists, even though currently lacking
methods, have an anti-ageing goal for humans? Might it be a longerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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month, 1-year, 5-years, or 10-years? If so, further crowding and territo-
rial wars are to be expected on our planet, unless a pervasive birth-
limiting process will occur. Or would signiﬁcant life-lengthening be for
a select few, presumably trillionaire enthusiastic emulators of Methuse-
lah? To be beneﬁcial, any increased life-length for a person must be
associated with continuing useful function of the various organs, espe-
cially the brain and neuromuscular system. Or is that our goal – to
keep the machinery running, better but not longer, with limited war-
ranties. Can we, with concerted endeavor, get all our elders bounding
around like jackrabbits?
1.4. Scope
This article is ofmore limited scope. It is a view, frommypersonal ex-
perience, of important histochemical-pathologic and clinical-pathologic
ﬁndings related to ageing of the neuromuscular system. It considers how
one might identify and correct, or prevent, the mechanisms of some
ageing-related damages to make more enjoyable the full-length of indi-
vidual life as governed by the other tissues e.g., blood-vessels, blood,
heart, kidneys, liver, lungs, brain. Currently the terribly frustrating
(and ultimately life-threatening) converse sometimes occurs: a person,
usually elderly, with a normally-functionally brain becomes progres-
sively trapped in a deteriorating body whose neuromuscular system
cannot respond to even the simplest command, such as with ALS (v.i.).
1.5. All of our body cells and tissues relentlessly age, and molecules can
become sticky
Tissues often shrink and dysfunctionalize in numerous ways. In
ageing, our tired and worn-out cellular proteins and other molecules
eventually malfunction – they then, or preferably somewhat before,
are quietly disposed of, especially through our proteasome and
autophagosome-lysosome catabolic pathways, and are replaced with
the refreshing youth of newly synthesized molecules. But prior to
their complete disposal, age-altered molecules may become modiﬁed
in various detrimentalways, including becoming “sticky”, and gradually
gum-up vital cellular molecular functions, e.g. of mitochondria, reticu-
lum, plasmalemma, and even the faltering disposal systems themselves
(also note Amyloidosis, v.i.).
1.6. “Slings and arrows of outrageous fortune” (SAOF's)
Rather universally our ageing muscles weaken and atrophy, and
sometimes suffer in various other ways from the (SAOF's) [3]. Physi-
cians and scientists attempt to “take arms against a sea of troubles
(SOT's). And, by opposing, end them” (ibid).
That is our job-description.
1.6.1. “You're just getting old”
This is not a diagnosis of neuromuscular symptoms, and too often it
is used dismissively by clinicians. Such fatiguing andweakening, numb-
ing and hurting neuromuscular patients deserve a full neuromuscular
evaluation, including muscle biopsy diagnostic histochemistry, electro-
myography, nerve conductions, blood tests, and often spinal-ﬂuid
examination.
The terms “normal aged person” or “normal-control aged person”
are indeﬁnable and oxymoronic, because all features of ageing are path-
ologic compared to the age-20–30 coterie.
Ageing is a risk-factor for muscle atrophy, but it does not reﬂect a
singular molecular cause.
1.7. Histochemistry background
The data and opinions stated herein are based on our personal expe-
rience, performing the histochemistry of N8000 diagnostic musclebiopsies obtained under local anesthesia. All ﬁndings and concepts pre-
sented here relate to the human neuromuscular system (unless stated
otherwise).
1.7.1. Histochemical techniques we use
On rapidly fresh-frozen, 10 μm parallel transverse sections of each
muscle, or nerve, biopsy, we perform: a) the Engel trichrome (eTri)
which we speciﬁcally modiﬁed for application to fresh-frozen sections
of humanmuscle [4,5] and now is universally used; b) 15 additional his-
tochemical reactions; and c) often other speciﬁcally-indicated ones, e.g.
the Askanas congo-red ﬂuorescence technique for amyloid [6] and the
immunolocalizations for phosphorylated tau and amyloid-β (which
are ageing-modiﬁed, congophilic proteins typically accumulated within
sIBM muscle ﬁbers (v.i.), and Alzheimer brain).
1.8 Neuromuscular SAOF's (also see below). Simplistically, neuro-
muscular SAOF's can be exogenous or endogenous.
a. Exogenous: These include viral and othermicrobes; irradiation from
our star (the sun) and other physical assaults; andmolecular toxins,
organic or inorganic, including prion-like misfolded or otherwise
dysfunctionalized molecules having cell-disturbing properties.
b. Endogenous: e.g.: erstwhile-normalmolecules that are pathologically-
altered, by oxidation or another deleterious process, to become
misfolded , sometimes “sticky”, and interferewith functions of normal
cellularmolecularmetabolic processes. Also, there can be genetic mu-
tations resulting in autogenous hypofunctioning or toxic proteins.
2. Succinct biology of the normal neuromuscular system
All ageing persons eventually have some degree of progressive fati-
gability, weakness and slowness, accompanied by visible atrophy of
muscles. This weakness frequently is a cause of falling, which can result
in serious injury, and sometimes death. In health, the muscle ﬁber is
maintained by its own salutary trophic metabolic processes, and by tro-
phic inﬂuences dispensed from its innervating lower motor neuron
(LMN), which are received at each muscle-ﬁber's single neuromuscular
junction (NMJ). The LMN itself is inter-dependent on normal trophic fac-
tors a) retrograde from its myoﬁbers at their neuromuscular junctions,
b) from the numerousmyelin-containing Schwann cells (SCs) surround-
ing its long axonal process, like oblong beads on a string, and c) by cir-
culating trophins, e.g. testosterone. Each LMN in the human biceps is
responsible for inducing, trophically-maintaining, and activating about
200 muscle ﬁbers and, via trophic inﬂuences, for the continuing trophic
maintenance of good health and type-speciﬁcity of those muscle ﬁbers.
The pattern of LMN discharges is especially important for trophic control of
its myoﬁbers, and possibly of its schwann cells [7]. We therefore hypoth-
esized that there are, respectively, type-1 and type-2 LMNs, and A and
B subtypes of each, but we were not able to histochemically distinguish
these putatively different LMN types [8–10].
2.1 AMotor-Unit (MU) refers to one LMN, its Schwann cells, and the
muscle ﬁbers it innervates. A neuromuscular disorder is one arising from
abnormality of any part of the motor-unit.
The lowermotor neurons and lower sensory neurons have a vital inter-
dependence with the Schwann cells that coat and nurture their axonal
extensions – the neurons cannot survivewithout theirmature Schwann
cells, and vice-versa. Just as trophic factors from lower motor neurons
induce and control the special type-1 versus type-2, and subtype, char-
acteristics of the muscle ﬁbers they innervate, the LMNs probably also
induce andmaintain hypothetically different type-1 and type-2 Schwann
cells respectively on themselves. And, probably the Schwann cells on
sensory neurons are different from ones on motor neurons, because
clinically there can be anti-Schwann-cell dysimmunediseases that rath-
er selectively affect eithermotor or sensory neurons, and even selective-
ly large-diameter sensory nerve ﬁbers (faster-conducting, conveying
position, vibration and touch sensations) vs. small-diameter sensory
nerve ﬁbers (slower-conducting, conveying pain signals).
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Physiologically, type-1 muscle ﬁbers are considered to be “slow-
twitch” and rather “fatigue-resistant”, while the type-2 ﬁbers are
“fast-twitch” and “fast-fatiguing” – as found in normal mammalian
muscle [11,12] and corroborated in human muscle [13]. The designa-
tions “slow-twitch” and “fast-twitch” for human muscle we introduced
[4] to distinguish the twitch properties of all mammalian-limb twitch-
muscle ﬁbers from the very-different amphibian non-twitch,
extremely-slow “tonic” ﬁbers of the thigh adductor clasp muscles [4,
11,12,14,15]. Morphologically, we speak only of what we see, type-1
and type-2 ﬁbers and their subtypes.
2.3.Motor units can be likened to Trees (Fig. 1). “I think that I shall al-
ways see a motor-unit as a tree” (apologies to Joyce Kilmer).
2.4 Autumn leaves (Fig. 1).
3. Clinically-evident “muscle atrophy of ageing” (MAA)
This is our intentionally-general descriptive term. We disagree with
the common assumption that MAA is strictly myogenous (i.e. that it re-
sults from a process involving only muscle but not LMNs).
3.1. Generalized muscle atrophy
Based on our clinical and laboratory evidence, it appears, in various
circumstances, that generalized muscle atrophy is often, or perhaps
nearly always, basically neurogenic, i.e. caused by malfunction of the
LMNs, or by the Schwann-cells' trophic inﬂuence on their LMNs.
Because of its near-universality and clinical importance, MAA will beFig. 1.Diagram (left) of lowermotor-neurons as deciduous trees, themuscleﬁbers represented
are longer, some more tortuous, some narrower than others. As an affected motor-neuron's tro
(leaves) typically suffer earlier, a “dying-back phenomenon”. In actual trees (right), as the suppl
orange, but are still on their tree, the color-change equivalent to dysinnervatedmuscle ﬁbers. Th
the top of the tree have totally lost their fallen leaves, like totally denervatedmuscle ﬁbers. (Fig
transverse sections of human fresh-frozen diagnostic biopsies, except 2E which is experimentaemphasized and initially discussed in regard to some facets of the
known and putative malfunctions in relation to the motor-unit compo-
nents, their causes and, brieﬂy, their potential treatments [16].
We use “Muscle Atrophy of Ageing” (MAA) [16] and never the ob-
fuscating term “sarcopenia”, which sounds like a deﬁnitive diagnosis
but it is not. “Sarcopenia” is often erroneously interpreted as desig-
nating a singular pathogenesis, but it does not. It simply refers,
imprecisely, to muscle atrophy in aged animals or humans – it does
not indicate or imply any pathogenic mechanism, of which there
can be a number of possibilities. In fact, from our histochemical stud-
ies we conclude that much of humanMAA probably has a major neu-
ropathic component. For an ageing patient complaining of muscle
fatigue and weakness, to state a “diagnosis” of “sarcopenia” is mean-
ingless – it adds nothing beyond the patient's own chief complaint.
3.2 Human MAA histochemically is typically manifest as: a) ordinary
dysinnervation/denervation atrophy, b) preferential type-2, or type2B,
myoﬁber atrophy, or c) both (v.i.).
3.3 Muscle Atrophy of Ageing is not a deﬁnitive clinical diagnosis, no
more than is “anemia” or “jaundice” or “stroke” – it is a reason to look
carefully, in each individual patient, for a cause, and especially for a
treatable cause [17]. Several known causes are described below.
3.3.1Whether there is also a general pervasive cause (or causes) of MAA
that eventually afﬂicts the neuromuscular system of every ageing person
is not known. Studies seeking a general, nearly-universal cause typically
do not intensively seek, in individual patients and in experimental ani-
mals, the possible presence of an identiﬁable known and potentially-
treatable primary, or coexisting, cause such as: dysimmune peripheral
neuropathy; nerve-rootmechanical radiculopathy; hyperparathyroidism
(v.i.) [16,17]; B12 v.i., B1 or other deﬁciency; or general malnutrition.as their trophically-nourished leaves. In each tree, some arborizations of distal axonal twigs
phic inﬂuence on its muscle-ﬁbers wanes, the distal axonal twigs and their muscle-ﬁbers
y of seasonal trophic sap begins towane, the autumn leaves initially change color, such as to
emost proximal lower leaves are still their normal green, while the distal “axonal” twigs at
s. 2 and 3. All histochemical preparations, stained with various reactions, are muscle-ﬁber
l.)
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In general, the causes and mechanisms are poorly understood. Ma-
ture normal muscle ﬁbers are post-mitotic cells, as are motor neurons.
A mature muscle ﬁber (muscle cell) is multinucleated, having about
2×104 nuclei distributed along its length of about 70–80 mm. Cellular
ageing can probably involve abnormalities of any or all subcellular sys-
tems, including mitochondria, endoplasmic reticulum, plasmalemma,
and aqueous and nuclear components. Proteasome and lysosome deg-
radations are especially important to dispose of the aged, potentially de-
ranged and disturbing proteins. Oxidative stress and endoplasmic
reticulum stress are also proposed to play important roles in ageing.
The “proteome” designates the large and varied family of proteins of a
cell, the proﬁle of which is cell-type speciﬁc. But which abnormality is
the initiating ageing defect, the sine qua non for MAA [17]?4.1. Is there a master-gene vitalostat?
Are the general ageing changes of cells due to effects of a still-
obscure omnipotent “master-vitalostat”, such as a “master-gene” acting
like a rheostat that gradually turns down the vitality of the cell? If there
is a master-rheostat, what during “before-ageing” keeps atrophy sup-
pressed, but thenwith ageingwhat initiates the turning-down and, con-
versely, what are the key steps by which it executes that turndown?
What are the underlying genetic factors, and any important epigenetic
mechanisms?
4.2 Philosophically, why are all living creatures programmed from
“conception” to die? Currently the muscle frailty associated with MAA
is universally inevitable, like the ageing-related more-visible frailty
and atrophy of skin, the failure of estrogen in menopausal women and
the gradual petering-out of testosterone in ageing men, accumulation
of wear-and-tear lipofuscin pigment within lower-motor neurons and
muscle ﬁbers? Is the most essential mechanism that starts and perpet-
uates MAA something we all ingest, or do not ingest; is it cumulative
subtle solar or cosmic irradiation; or perhaps something else to which
we all are exposed? Is there a gradual cellular accumulation of mole-
cules cumulatively more toxic than lipofuscin – such as oxidatively
damaged or toxically misfolded proteins – that gradually “rust” normal
cellular functions and activate “atrophy processes”? Can any of the
pathogenic mechanism(s) contributing toMAA be prevented or treated
now? Much work needs to be done before we can prescribe an elixir to
make our elders jumping jubilantly.4.2. Are there three hypothetical master-genes?
In the atrophy process, probably there are multiple stages and path-
ways participating, someofwhich, if identiﬁable,might become amena-
ble to future not-yet-developed treatments (v.i.). For skeletal muscle,
might there be three hypothetical “master-genes”, “Fiberatrophin-2”,
“Fiberatrophin-2B” and “Fiberatrophin-1”, which are normally inhibited
– but when activated or disinhibited by an atrophy-promoting factor
they unleash cascades of other activations and inhibitions, resulting in
preferential atrophy of type-2, type-2B and type-1muscle ﬁbers respec-
tively. Preferential type-2/2B ﬁber atrophies are discussed below.
4.3.1 Preferential atrophy of type-1 ﬁbers is seen in type-1 “myo-
tonic atrophy” (myotonic dystrophy) [18,19], a disease caused by ex-
pansion of CTG trinucleotide repeats of the gene DMPK; the atrophic
myoﬁbers strongly resemble atrophic ﬁbers of ordinary denervation
[18,19]. “Preferential type-1 ﬁber hypotrophy” is seen in “type-1 ﬁber
hypotrophywith central nuclei” [20] (sometimes called “myotubular
myopathy”, although the small ﬁbers are more mature and type-
speciﬁc than embryonic myotubes; the disease in some patients is
attributable to a genetic mutation of myotubularin, myogenic-
factor-6, or dynamin-1 [21].5. Neuromuscular histochemistry, details
Normal skeletal muscle is composed of muscle ﬁbers that are very
long cylinders, their length being about 1000-times their typical diame-
ter of about 45-65 μm (in biceps).
Transverse histochemical sections of muscle biopsies are the more
informative.
5.1 The Engel trichrome [4,5] is the now universally-used ﬁrst stain for
general histochemical evaluation of a muscle or nerve biopsy The histo-
chemical types of human muscle ﬁbers are most distinctively delineated
by two myoﬁbrillar ATPase reactions: a) the “regular-ATPase”
(regATPase) incubated at pH 9.4 [22], and b) the acid-preincubated “re-
verse-ATPase” (revATPase) [23]. (Some myopathologists also use anti-
bodies against different types of myosin for ﬁber-type deﬁnition.) In
normal adult human muscle, ﬁbers lightly-stained with reg-ATPase and
reciprocally dark with rev-ATPase are arbitrarily designated “type-1 ﬁ-
bers”, while the ﬁbers oppositely stained are “type-2 ﬁbers” [4,24]. The
type-1 ﬁbers are high in most of themitochondrial oxidative-enzyme ac-
tivities (e.g. cytochrome oxidase [COX], succinate dehydrogenase [SDH],
and β-hydroxybutyrate dehydrogenase [HBDH]), as well as inmyoglobin
and triglyceride droplets; and they are low in the anerobic-glycolysis en-
zymes myophosphorylase and UDPG-glycogen transferase, in glycogen,
and in the aqueous sarcoplasmic enzyme lactate dehydrogenase. The
type-2 ﬁbers are oppositely-stained with those reactions. The very-
useful mitochondrial oxidative-enzyme menadione-mediated α-
glycerophosphate dehydrogenase [MAGPDH] is stronger in type-2 ﬁbers
[25].) Type-1 ﬁbers havemore capillaries adjacent to them and are better
equipped for oxidative metabolism, and clinically are utilized for
prolonged muscle activity. The type-2 ﬁbers are better equipped for an-
aerobic glycolysis, and clinically are utilized for short bursts of more in-
tense activity. The normal type-2B ﬁbers are evident as having an
intermediate degree of staining with the revATPase [26].
5.2 Myoﬁber types and subtypes can have a selective or non-
selective response to various abnormalities.
6. Muscle ﬁber distribution pattern, as viewed in transverse sections
(in all histochemistry Figures)
6.1. Reinnervation following recent denervation, type-grouping
Normally, muscle ﬁber types are rather evenly intermixed, and
muscle-ﬁbers of an individual LMN are not in a tight group. Muscle
ﬁbers can “switch” their histochemical type if denervated and then
reinnervated by a type of LMN different from their original
innervating LMN type (i.e., “foreign reinnervation”). Denervated
muscle ﬁbers apparently can promiscuously accept comforting rein-
nervation from any type of LMN, a phenomenon commonly occur-
ring in chronic neurogenic diseases that have been demonstrated
experimentally in nerve-crush + reinnervation experiments
[27–31]. In human muscle, this seemingly-random foreign reinner-
vation results in “type-grouping” (Fig. 2D)– which is evident as
smaller or larger groups of the same histochemical ﬁber-type replac-
ing the normal, rather even inter-mixture of individual type-2 and
type-1 myoﬁbers. Type-grouping seen in a patient's diagnostic mus-
cle biopsy is considered a manifestation of “established reinnerva-
tion”, namely previously-denervated orphaned muscle ﬁbers having
been successfully reinnervated by neurite sprouts from nearby
relatively-healthy LMN's of a foreign type and incorporated into
their larger, now more ﬁber-dense motor-unit. In biopsies of ageing
patients we have not noted a general increase of type-grouping.
6.2. Switching ﬁbers and regen-degen ﬁbers can have an abnormal,
intermediate degree of myoﬁber staining
In abnormal muscle, an intermediate degree of myoﬁber staining
with both ATPases suggests: a) partially converted ﬁbers in the process
Fig. 2. 2A,B – Recent denervation without innervation, evidenced by small, dark angular muscle ﬁbers. Pan-esterase staining, Amyotrophic Lateral Sclerosis. A ×1330, B ×2000. 2C – End-
stage of denervation, evidenced by very atrophic muscle ﬁbers with their clumps of pyknotic nuclei (the NADH-TR stain shows that such “end-stage” atrophic ﬁbers typically have high
activity, indicating that they are alive). Chronic untreated dysimmune peripheral neuropathy, Engel trichrome stain ×3330. 2D – Established reinnervation, indicated bymuscle ﬁber type-
grouping, in chronic dysimmune peripheral neuropathy. (Most type-grouped ﬁbers have retained, or re-achieved, their normal diameter after successful “foreign reinnervation”.) Darkly-
stained type-2 muscle ﬁbers and lightly-stained type-1 ﬁbers are type-grouped, in contrast to what normally would be a rather even intermixture of ﬁber types. (There is also some
type-2 ﬁber smallness of the dark ﬁbers.) Regular ATPase reaction at pH 9.4, 830×. 2E – Diffusely greater atrophy of the dark type-2 ﬁbers, 27 weeks following experimental total dener-
vation without reinnervation, guinea pig [22], Regular ATPase. ×500. 2 F, G – Type-2 ﬁber atrophy in 2 males – the darker-stained type-2 ﬁbers diffusely are of smaller diameter than the
lighter-stained type-1 ﬁbers, whereas in normal men the type-2 ﬁbers have a larger diameter than the type-1 ﬁbers. There is also a slight paucity of type-1 ﬁbers in G. F – Chronic
dysimmune peripheral neuropathy; G – Chronic glucocorticoid toxicity. Regular myoﬁbrillar ATPase, pH 9.4. F ×2000; G ×2500. 2H – Preferential atrophy of the intermediate-stained
Type2B ﬁbers. Partially-reversed ATPase clearly shows the 2B ﬁbers (some indicated by small arrows). Weakness and severe fatigue from hyperparathyroidism. ×1880.
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ropathic phenomenon (although in amyopathy there can sometimes be
“myogenous de-innervation” due to muscle-ﬁber abnormality at or near
the neuromuscular junction with reparative sealing and survival of the
more distal portion of the ﬁber thereby cut off from the innervation in-
ﬂuence and thus able to accept foreign reinnervation) [32]; and
b) regenerating (“regen-degen”) muscle ﬁbers (RNA-positive, often
alkaline-phosphatase-positive [33] and slightly acid-phosphatase posi-
tive), which are usually evident in the setting of a myopathy, although
a few can occur in a prominent denervation.6.3. Fiber-type paucity
Clinically, a relative “paucity” of one type of muscle ﬁber in a
patient's biopsy can be caused, hypothetically, by: a) preferential impair-
ment of the corresponding type of LMNs or Schwann cells; b) if both
LMN types are equally abnormal, preferentially more successful sprouting
and reinnervation ability of the opposite type of LMNs; c) if there are
large groups of both types ofmuscleﬁbers in a chronic reinnervation sit-
uation, biopsy sampling could produce a non-representative impression
of paucity; or d) preferential myopathic loss of that type of muscle ﬁber.
(We use the term “ﬁber-type paucity” [30] and not “ﬁber-type-predom-
inance” because it is more likely that the too-few muscle ﬁbers reﬂect
the abnormality.)6.3.1. MAA or “Elder atrophy”
In our muscle biopsies of elderly patients, we have observed that
type-1 ﬁber-paucity is evidentmore frequently than type-2ﬁber paucity,
whereas a preferential atrophy, if present, is of type-2/2B ﬁbers (WK
Engel – unpublished observations). In ageing humans it is uncertain
whether there is a gradual impairment or loss of spinal cord LMNs. If
there is, possibly the type-1 myoﬁber paucity could be due to an
ageing-associated gradual preferential loss of type-1 LMNs, while a pu-
tative dysinnervative enfeeblement of type-2 LMNs might be causing
the type2/2B atrophy.
7. Ordinary neuropathic atrophy and type-2/2b ﬁber atrophy are the
two most common pathologies found in muscle of ageing persons
Observationally, we consider that there are two histochemical “cat-
egories” of patient muscle-ﬁber atrophy:a) Ordinary Dysinnervation/Denervation Atrophy (typically the small an-
gular ﬁbers of all ﬁber-types (Fig. 2A,B), often (but not always) NADH-
tetrazolium-reductase (NADH-TR) and pan-esterase dark (note that
with these two reactions, normal type-1 ﬁbers are darker) ; and…
b) Preferential Type-2/2B Muscle Fiber Atrophy (Fig. 2E-G) [34,35] (typi-
cally small roungulated, and occasionally angulated ﬁbers being “only”
2/2B ﬁbers).
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(i) Greater catabolism than synthesis of muscle-ﬁber proteins, espe-
cially catabolism of myoﬁbrillar proteins, which occurs mainly
through two subsystems: proteasome and autophagy/lysosome
[37,38].
(ii) Decreased synthesis of muscle protein, which is less well-
established as possibility contributing to myoﬁber atrophy.
(In denervation atrophy, the menadione-mediated α-
glycerophosphate-dehydrogenase reaction is useful because it
sometimes stains some of the atrophic and roungulated type-2
ﬁbers abnormally dark.)
Whereas conceptually, Type-2/2B Fiber Atrophy could be either
Neurogenous or Myogenous, or Both, we think it as usually neurogenous
(v.i.) [36]. Determining which cause(s) applies to the ﬁber atrophy in
each speciﬁc patient is essential for establishing patient-speciﬁc treat-
ment. (“Atrophy” refers to shrinkage from a previously-normal diame-
ter, while “hypotrophy” designated myoﬁbers that initially failed to
achieve normal diameter.) Other less common causes of myoﬁber
smallness are: Type-1 ﬁber atrophy in myotonic muscular dystrophy;
incomplete regeneration, muscle ischemia and myoﬁber splitting
longitudinally.8. Neurogenic atrophy
Neurogenic Changes include: a) “Dysinnervation”(of which we con-
sider preferential Type-2/2B ﬁber atrophy to often be an example [17]);
b) Reversible-Denervation; Irreversibly-Denervation; Extremely-
Atrophic Pyknotic Nuclear Clumps; and c) Reinnervation. Distinct histo-
chemical or immune markers for these different stages are not
established, but could be interesting.8.1. Progressive worsening of these neurogenic changes probably occurs as
diagrammed
Normal ←→Dysinnervated (±2/2B atrophy) ←→ Reversibly
Denervated (±2/2B atrophy) → Irreversibly-Denervated (±2/2B
atrophy)→Pyknotic-Nuclear-Clumps
8.2. “Dysinnervation is our hypothetical concept [16] of only partially-
impaired, incomplete-loss of neural inﬂuence, especially of molecular
neurotrophic factors, while some of them are still able to be produced
from crippled but alive motor neurons (Fig. 1; Diagram). This
“dysinnervation” phenomenon can be conceptualized as having some as-
pects like a persistence of the early stages of “ordinary recent denerva-
tion”, to which it appears histochemically similar. Dysinnervation could
produce some clinical weakness of the affected ﬁbers.
8.2.1Denervation is the complete loss of LMN inﬂuence on themuscle
ﬁbers, and it produces completeweakness of the affected ﬁbers (Fig. 2A,
B).8.1.1. Pan-dysinnervations and pan-denervations in regard to type-2/2B
ﬁber atrophy (Fig. 2E-H)
These are postulated to adversely affect mainly the Type-2 ﬁbers
(or sub-preferentially type-2B ﬁbers) by lack of adequate trophic
inﬂuence on the muscle ﬁbers, either: i) partially – quantitatively
or qualitatively – (in pan-dysinnervations), to which type-2 muscle
ﬁbers (or sub-preferentially type-2B ﬁbers) are more susceptible,
or ii) fully (in pan-denervations). Denervations always, and
dysinnervations probably often, produce fatigue and weakness, the
degree being in relation to the number and severity of the muscle
ﬁbers dysinnervated.8.2. Muscle biopsy can help establish the neuromuscular component of
often-difﬁcult clinical problems
We have seen a number of patients diagnosed elsewhere as having
“Chronic Fatigue Syndrome”, “Fatigue State”, ”Fibromyalgia”, Diffuse
Cramps Syndrome”, “Psychological”, or “You're Just Getting Old”, who ac-
tually had deﬁnite type-2/2B ﬁber atrophy, and frequently also with as-
pects of ordinary denervation. In some we have found the cause to be:
an adenomatous hyperparathyroidism (Fig. 2H) [16,17], cured by surgical
parathyroidectomy; dysimmune neuropathy (CIDP) treatable with IVIG;
or myasthenia gravis responsive to prednisone + azathioprine, or to
IVIG ± thymectomy v.i. [39,40].)
8.4 Dysinnervations [16]. These can occur in disorders of:
8.2.1. Lower-motor-neurons, at the level of the soma, roots, or proximal or
distal axons
Dysinnervations can clinically be evident by hyperactivity or
hypoactivity of the LMN's. Resultant hypoactivity would be manifest
as muscle fatigue or weakness. Examples of dysinnervation hyperac-
tivity are axonal abnormal electrical hyperactivity, which can pro-
duce multi-microcramps, fasciculations, and macrocramps [39]. The
multi-microcramps are presumably due to lability and persistently
aberrant ﬁrings of distal axonal twigs, caused by molecular abnor-
mality essentially at i) the distal axonal twigs themselves, or ii) pos-
sibly at their more proximal regions (including a possible initial
impairment of enveloping schwann cells at either level). Probably
the ﬂuctuating microcramps each involve just a few myoﬁbers
and produce migrating slight-moderate pain or discomfort, or
"discomforting insomnia". Fasciculations, caused by intermittent
LMN ﬁrings, can involve a few or more myoﬁbers and usually are
not painful. Large macrocramps, caused by rapid continuous ﬁrings,
usually affect most of the myoﬁbers of a muscle and can produce
sudden severe pain and painful-awakening insomnias.
8.2.2. Symptomatic treatment of these forms of hyperactive LMNs
a)must include absolute avoidance of all possible stimulants, such as
caffeine, theophylline, adrenergic medicines, and all “energy drinks”;
and b) can include small doses of clonazepam [39]. (Quinine used to
be excellent for these LMN hyperactivities, but it is now proscribed by
the FDA – the background for that restriction might merit review, to
see if it was based on cardiologic doses of quinine much higher than
ones that were widely useful for treating muscle cramps.)
8.2.3. More severe dysinnervation could produce electrically-silent muscle-
ﬁber atrophy
Muscle atrophy electrically-silent at rest also occurs at various
stages of the pan-dysinnervation of type-2/2B atrophies. Routine
clinical EMG measuring the size of voluntary motor-unit potentials is
done at slight muscle contraction, which preferentially activates
Type-1 ﬁbers, and thus does not see the later-recruited type-2/2B
motor-units – consequently it probably does not see most pure
type2/2B atrophies, but would see spontaneous activity at rest if
there were any.
8.5 Dysinnervations can produce clinical fatigue and weakness, in rela-
tion to the quantity and quality of the neural impairment [16].
8.3. Schwann cells
Trophism from functionally-mature Schwann-cells to LMN axons
is vital for the normal function and survival of those LMNs.
Dysschwannian peripheral neuropathies are the result of Schwann-
cell malfunction causing a secondary impairment of the proximal
or distal portions of the axons or somas of their trophically nourished
lower motor and sensory neurons (dysschwannian neuropathy pro-
duces symptoms only when the affected Schwann cells do not
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neuronal axons they surround):
Normal ←→Reversibly-Dysschwanned Axon ←→ Reversibly-
Deschwanned Axon→ Irreversibly-Deschwanned Axon→ Irreparably-
Impaired Axon
Examples of dysschwannian neuropathies include: (i) CIDP, AIDP
and other dysimmune neuropathies; (ii) diabetes-2 dysimmune neuropa-
thies; (iii) genetico-diabetoid-2 dysimmune neuropathies; and (iv)
various non-dysimmune neuropathies.
8.4. Recent denervation without reinnervation compared to type-2/2B ﬁber
atrophy
When slightly to moderately evolved, recent denervation without re-
innervation is manifest (in transversely-cut muscle ﬁbers) as small
angular-contoured (“angular”) ﬁbers which are often, but not always,
excessively dark with the NADH-TR and/or pan-esterase and/or
menadione-mediated α-glycerophosphate-dehydrogenase reactions
(Fig. 2A,B) – sometimes those ﬁbers are low in myophosphorylase
and/or COX reactivity. Slightly or moderately small “roungulated”
(shape between rounded and angulated), often “pre-angular”, muscle ﬁ-
bers can indicate either early recent denervation or type-2/2Bﬁber atro-
phy, the latter evidenced, in its early- and mid-stages as more
roungulated than angular atrophy.
8.4.1. Target ﬁbers
The sometimes-evident 3-zoned “target ﬁbers” in muscle (found
only in type-1 ﬁbers) are another sign of impaired innervation [41]. In
an otherwise neuropathic biopsy, the 2-zoned “targetoid ﬁbers” are
probably of the same neurogenic pathogenesis as target ﬁbers; but be-
cause they are histochemically indistinguishable from central-core dis-
ease ﬁbers (also found only in type 1 ﬁbers [24,36], they are called
“targetoid-core ﬁbers” and might have some pathogenic features in
common.
8.4.2. Recent denervation, early and mid stages
In those early and mid-stages, e.g. from amyotrophic lateral sclerosis
(ALS) or peripheral neuropathy, on transverse sections there are typically
scattered (not grouped) small, angular-contoured ﬁbers, whose angular-
ity seems to be due to their being slightly indented by the adjacent nor-
mal ﬁbers, which apparently have greater internal hydrostatic turgidity
pressure than the denervated ﬁbers. By contrast, in early and mid-
stages of type-2 ﬁber of atrophy, many of the type-2 ﬁbers, or the 2B
subset of ﬁbers (Fig. 2H), are more roungulated and are, among them-
selves, in a similar stage atrophy. In total or nearly-total acute recent de-
nervation (pan-denervation), e.g. in the Acute Immune Dysschwannian
Polyneuropathy (AIDP) of Guillian-Barré disease, the denervated ﬁbers
are rather roungulated, probably because there are no adjacent
normally-turgid muscle ﬁbers to concave their contours. Regarding
type-2/2B ﬁber atrophy in what seems to be an advanced stage of atro-
phy, there are ﬁbers that have become very small and usually angular.
Arbitrarily, in a setting of type-2/2B ﬁber atrophy we consider such
small angular ﬁbers and pyknotic nuclear clumps as evidence of pro-
gression to a denervation status. Any concurrent type-grouping would
indicate established reinnervation following previous denervation.
8.7.3 Our experimental surgical pan-denervation of a muscle, without
allowing reinnervation, produced preferentially greater atrophy of type-2
ﬁbers v.i. (Fig. 2E) [28,30]. Accordingly, the neurogenic kind of type-2
ﬁber atrophy is proposed to be a dysinnervation that evolves into dener-
vation (see Fig. 1 & Diagram).
8.5. Pan-dysinnervation and Pan-denervation can, hypothetically, be man-
ifest as type-2/2B ﬁber atrophy
This can be i) without, or ii) with associated features of ordinary
recent-denervation and/or established-reinnervation [16]. When thereis coexisting type-2 ﬁber atrophy and small angular ﬁbers like those of re-
cent denervation, it can be difﬁcult to decidewhether the interpretation
is: a) two separate processes consisting of type-2 ﬁber atrophy plus re-
cent denervation, or b) only type-2 ﬁber atrophy and the small angular
ﬁbers representing the advanced state of the type-2 ﬁber atrophy. The
presence of at least some type-grouping (established reinnervation)
would indicate the presence of at least some actual denervation-
reinnervation. Most examples of type-2/2B ﬁber atrophy do not have a
component of type-grouping [Engel WK, unpubl].8.5.1. End-stage Non-reinnervation following previous denervation
This is evident as “pyknotic nuclear clumps” of extremely-atrophic
ﬁbers (Fig. 2C). This end-stage can have surprisingly long-persisting
pyknotic nuclei, possibly formonths, someofwhich can show some fea-
tures of apoptosis, such as DNA fragmentation by Tunel staining – that
has been termed “apoptosis lente” [42], because ordinary apoptosis is a
more rapid process, completed in hours.9. Type-2/2b ﬁber atrophy in ageing humanmuscle: description and
new concepts
9.1. Possibly concurrent causes
The topic of Type-2/2B ﬁber atrophy is large and complex, and the
subject of various experimental animal studies – some of our personal
concepts and general principles in humans [16] are discussed here.
Even in an individual patient, a Type-2/2B ﬁber atrophy might have
more than one cause, or it might coexist with ordinary denervation.9.2. Type-2/2B ﬁber atrophy, general principles (Fig. 2E-H)
The type-2 muscle ﬁbers are more structurally labile, and especially
are the type-2B ﬁbers. In human skeletal muscle, the type-2/2B ﬁbers
are: a) more prone to atrophy, which occurs in various clinical condi-
tions such as glucocorticoid toxicity (Fig. 2G), disuse, cachexia, remote-ef-
fect of a neoplasm, and male animal castration, and strikingly in
experimental total denervation without allowed reinnervation [28,30];
and b)more prone to hypertrophywithwork, especially inmen. In aver-
age young-adult men, the diameter of type-2 ﬁbers is larger than of
type-1 ﬁbers, but in average young-adult women type-2 ﬁbers are
smaller than type-1's – that gender difference has been attributed to
more circulating testosterone in men, and there might be additional
considerations. There are two subtypes of normal type-2 ﬁbers, 2A and
2B. At slightly less acidic (or shorter) pre-incubation for rev-ATPase
staining, the 2B ﬁbers have properties intermediate between the 2A
and the type-1 ﬁbers. Often in a type-2 ﬁber atrophy the subtype-2B ﬁ-
bers are more atrophic (Fig. 2H). (Note: If the type-2B ﬁbers are not dis-
tinguishable in the initial revATPase staining, that might be because the
acid preincubationwasnot exactly right for that specimen– in addition-
al stainings with slightly varied acidic pHs the 2B ﬁbers might become
evident [23].) There are also two sub-types of type-1 ﬁbers, 1A and 1B,
but not yet of separate clinical importance.9.3. Prevalence of type-2B ﬁber atrophy
Not yet clariﬁed is our suggestion that the possibly that all examples
of “type-2 ﬁber atrophy” would show preferential type-2B atrophy if
type-2 ﬁber subtypes would always be histochemically evident. This
possibility could probably be achieved if, in the RevATPase reaction,
several different pHs of the acid-pre-incubation solution would be
tested – since that subtyping is not always established, we write
“type-2/2B” ﬁber atrophy.
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2 ﬁber atrophies basically neuropathic?
Because a total-denervation mechanism has been proven experi-
mentally to cause preferential type-2/2B muscle ﬁber atrophy v.s., in
any example proposed to be a “myopathic” type-2/2B atrophy, there
could instead be an underlying “neuropathic” aspect – in fact,…
9.4.1. In any 2/2B atrophy situation it might be difﬁcult to prove that a neu-
ropathic mechanism is not involved
9.5 For ageing human muscle, there is a paucity of information, in
contrast to a more abundant literature regarding muscle ageing in
animals (see [7,43–48]. The clinical and experimental muscle atrophies
associated with cachexia, hyponutrition (starvation), remote neo-
plasm (paraneoplastic), and glucocorticoid myotoxicity, a) all involve
preferential atrophy of type-2/2B ﬁbers, and, very importantly, b) have a
number of their biochemical degradative steps in common, including
strong similarities to experimental muscle totally-denervated without
reinnervation (See [28–31,38,46,47,49]. The biochemical similarities
between pan-denervation and the other causes of 2/2B atrophy
strengthen our histochemically-based hypothesis of the putative neuro-
genic basis of the various causes of type2/2B atrophy (v.i.). Accordingly,
the underlying cause(s) of 2/2B atrophies could be neurogenous, namely an
insufﬁciency of LMN inﬂuences (or perhaps in some situations amyogenous
dysreception of them).
9.5. Biochemical studies of muscle atrophy
There are a number of studies, by others, of animal muscle-ﬁber at-
rophy in ageing and in various imposed conditions. Some the results are
excerpted here, without detailed attributions. An introduction to that lit-
erature can be found through the following: [7,38,43,44,46–48,50–53].
9.6. Hypoactivity (“disuse atrophy”) is manifest as type-2/2B ﬁber atrophy
This atrophy can be attributed to net reduction of overall neural acti-
vation, which triggers catabolic processes, and inhibits anabolic ones,
within the muscle ﬁbers [7,49]. Causes include: supra-segmental CNS
disorders; general illnesses; cast on a limb; arthritic joint pains, and
psycho-social factors, such as depression, or “interminable television”.
This is histochemically and biochemically indistinguishable from early
stages of deﬁnite dysinnervation/denervation atrophy [W.K. Engel un-
published, and 38,43,44,46–48,50,52-54].
9.7. Histochemistry of atrophic ﬁbers of Type 2/2B ﬁber atrophy (Fig. 2E-H)
[54]
With the 2ATPases the atrophic 2/2Bﬁbers have their usual reciprocal
activities. Myophosphorylase appears to be in its usual abundance, at
least in most patients, differing from the usually reduced amount in
small angular ﬁbers of ordinary denervation. Some 2/2B atrophy ﬁbers
do seem to have somewhat, or even prominently, reduced oxidative en-
zyme activity (remembering that in normal type-2 ﬁbers most oxidative
enzymes are lower, v.s. (Speculatively, the atrophic type 2 ﬁbers could
have impairment of an unstudied glycolytic or other non-mitochondrial
enzyme involved in ATP production, or other important mitochondrial-
supporting functions, similarly, in principle, to the explanation I propose
for the prominent mitochondrial abnormalities found in our patient
with adult-onset myophosphorylase deﬁciency (Fig. 3D) (v.i.).
9.8. Is there a biochemical “ﬁnal common path” applicable to the pathogen-
esis of all type-2/2B atrophies?
Different human conditions are associated with preferential type-2/
2B ﬁber atrophy, raising the question of various possible pathogenic
mechanisms, or a singular one. In the individual patient, determiningwhich cause of the type-2 atrophy is most inﬂuential can lead to an ap-
propriate treatment. A ﬁnal common path to the type-2/2B ﬁber atro-
phies is not certain, but in experimental animals conditions associated
with at least several of the type-2/2B ﬁber atrophies have the same
major players, such as myostatin, the ubiquitin-proteasome proteolytic
system, ubiquitin ligases, the FoxO system, and the autophagy-
lysosome proteolytic/organellolytic system [38,43,44,46–48,50,52,53].
Even if a ﬁnal common pathogenic path is identiﬁed, ﬁnding a ﬁnal com-
mon elixir to produce eternal vigor could be difﬁcult.
9.9. Cautious interpretation of biochemical studies of human “muscle atro-
phy of ageing”
Biochemical studies of ageing human muscle could be relevant to
understanding the pathogenesis of ageing atrophy – only if, in the pa-
tients studied, the disorder is actually primary within their muscle ﬁbers,
which could be difﬁcult or impossible to ascertain.
9.9.1. Train-wreck, injured buffalo on the track
If in an example of type-2/2B ﬁber atrophy there is a major neuro-
pathic component, biochemical analyses of that muscle’s homogenate
are actually looking only at the train-wreck but not seeking the real an-
tecedent (upstream) cause of the locomotive's derailment:
an injured buffalo on the track. Consequently, identifying an underly-
ing causative dysinnervation/denervation component would require
moving the focus of pathogenic interest upstream to the lower motor
neurons and their Schwann-cells, and perhaps to spinal-cord juxta-
neuronal astrocytes and presynaptic neurons.
10. Biochemistry of muscle ﬁber atrophy
10.1. “Myogenous” biochemicalmechanisms resulting in type-2/2B ﬁber at-
rophy: might they actually be secondary to a neuropathic cause?
10.2“Atrogenes” are a common set of genes whose expression is co-
ordinately induced or suppressed in muscle during generalized wasting
states that are manifested as type-2/2B atrophy. These include: ageing,
fasting, cancer cachexia, renal failure, diabetes, disuse and experimental
denervation [38,43,44,46–48,50,52,53]. The atrogenes can be activated
by intrinsic or extrinsic abnormalities.
10.2. Is there a wearing out, a weariness of the cellular protective
mechanisms?
The normal muscle ﬁber, like all cells, has what we term a
“protectosome” (WK Engel, unpublished), a molecular team of beneﬁ-
cial factors that inhibit expression and consequences of atrophy-
producing atrogenes and hold in abeyance the atrophogenicmechanisms
(including martyring genes and mechanisms), with which the muscle
ﬁbers of all of us are normally equipped. The atrophogenic factors of
muscle are constantly ready to be unleashed to produce self-eroding/
self-catabolizing, a sort of gradual cellular suicide – this occurs when a
beneﬁcent protective system falters in an ageing cellular environment,
or in another circumstance leading to atrophy. The myoﬁber's internal
protective systems include control of any endogenous toxic misfolded
proteins and free radicals.
10.3. Myostatin
This is a negative regulator of muscle mass in normal development,
and it is an important factor limiting the size of mature muscle ﬁbers. A
normal level ofmyostatin is sufﬁcient to inhibit themyoﬁbrillar synthesis
rate and phosphorylation of S6K and rpS6 [38,43,44,46–48,50,52,53]. In
normal human muscle, it is not known which ﬁber-type normally ex-
pressesmoremyostatin, because with the antibodies we used immuno-
reactive myostatin was not detectable in either ﬁber type [55–57]. In
Fig. 3. 3A -Three “ragged-red”muscle ﬁbers (which are bright red with the Engel trichrome) here are highlighted by succinate dehydrogenase staining of theirmitochondria, excessively in
comparison to the surrounding normally-stained ﬁbers. ×3170. 3B –Many normal-diameter muscle ﬁbers (some indicated by asterisks) have complete absence of cytochrome-oxidase
staining (white ﬁbers in this photograph), intermingled with normal type-1 (very dark) and type-2 (slightly-dark) ﬁbers. ×1650. 3C - Disturbedmitochondrial activity in a patient over
age 70. A – “Moth-eaten” and “large central pallor” patterns in various muscle ﬁbers stained for succinate dehydrogenase activity. “Chronic Fatigue Syndrome”, ×3510. 3D –Muscle ﬁbers
showing regions of complete ormoth-eaten absence ofmitochondrial staining, in a patientwith adult-onsetmyophosphorylase activity deﬁciency (completely absentmyophosphorylase
was provedhistochemically and biochemically). This suggests that themanifestedmitochondrial abnormalitymaybe secondary to the glycolytic defect, (compare to image 3E). ×3170. 3E
–Muscle ﬁbers showing regions of complete or moth-eaten absence of mitochondrial staining, in a patient with adult-onset rod disease, also shown in 3 F,G. compare to 3D. Succinate
dehydrogenase, ×3450. 3 F – “Decrease-Increase” pattern in type-1 ﬁbers – this is a disturbed arrangement of mitochondrial staining, due probably to abnormality of both mitochondria
andmyoﬁbrils, and possibly also of stabilizing desmin ﬁlaments. This can be a “myopathic” phenomenon, in this case it is adult onset rodmyopathy; but it sometimes can be accompanying
recent denervation, Succinate dehydrogenase. ×4000. 3G – Adult-Onset Rod Myopathy, with IgG monoclonal gammopathy. The Engel trichrome showed the intra-myoﬁber rods in three
groups of small bright-red rod-shaped or dot-like structures (dark in this black-white picture). ×5530. 3H – Excessive triglyceride droplets in two normal-size muscle ﬁbers. With this pho-
tographic exposure, the staining of normal ﬁbers is only faintly evident in the lower part of theﬁgure.Oil red O stain. 3330×. 3I – The larger clumps of staining, usually peripherally located,
are associatedwith lysosomal lipofuscin granules. Although the lysosomal acid-phosphatase staining in everyone gradually increaseswith ageing, this amount of staining is excessive for this
man's age of 45 (it is more like that of someone age 85). Pan-esterase staining ×5830.
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protein/precursor-protein (Mstn/MstnPP), but not the mRNA, was
quantitatively increased and was immunohistochemically increased
preferentially in the atrophying type-2 muscle ﬁbers. It was alsoquantitatively increased in the atrophying muscle of sporadic
inclusion-body myositis, an ageing-associated disease [55–57]. We pro-
pose that increased myostatin could be an important pathogenic com-
ponent of the type-2/2B ﬁber atrophy of ageing. Also, Mstn/MstnPP
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atrophy in various situations. Quantitative increase of myostatin and
its mRNA has been reported by others in atrophic muscle (probably
type-2 ﬁber atrophy) associated with arthritis and with HIV [58], and
with glucocorticoid myotoxic type-2 ﬁber atrophy (referenced in
[55–57]). Elevated serum myostatin levels occur in end-stage liver dis-
eases, in which patients have profound muscle wasting. In animal
models of chronic heart failure, skeletal muscle myostatin is increased,
and treadmill exercise can mitigate that myostatin protein expression.
SomeBelgian cowswithmutated (ineffective)myostatin have enlarged,
but not stronger, muscles. It is uncertain whether the actual mecha-
nisms by which myostatin protein is pathologically increased would
be successful therapeutic targets. IGF-1 inhibits the effects of myostatin
and preserves skeletal muscle in mouse models of cachexia [38,43,44,
46–48,50,52,53]. Administration of ACTR2B-Fc inhibited myostatin and
muscle wasting in 2 models of cancer cachexia, without affecting
tumor growth [59]. Three-days of lower-limb suspension in humans
causes the unloaded (“disused”) muscles to increase myostatin mRNA
and protein. In aneurally cultured muscle ﬁbers, TNFα induced expres-
sion of myostatin through a p38MAPK dependent pathway.
10.5 Follistatin is a normal product of muscle that inhibits the effects
of myostatin. Although seemingly a logical anti-atrophy therapeutic
agent, it has not yet achieved any clinical usefulness for muscle atrophy
of ageing, nor for any other human muscle disorder.
10.4. The ubiquitin-proteasome system
This is a major site of protein catabolism in muscle-ﬁber atrophies,
and that activity is up-regulated by ubiquitin ligases MuRF1 andMAFbx
(Atrogen-1) [38,43,44,46–48,50,52,53]. They target particular protein
substrates for their degradation via the ubiquitin-proteasome pathway.
The growth factor IGF-1 can block that upregulation. MURF substrates
include components of themuscle sarcomeric thickﬁlaments, especially
the myosin heavy chain. In denervation or fastingmuscle atrophy, there
is loss of: myosin-binding protein c and myosin light-chains 1 and 2
from the myoﬁbrils before any measurable decrease of myosin heavy
chain [38,43,44,46–48,50,52,53]. This selective loss requires MuRF1.
Myosin heavy-chain (MyHC) itself is somewhat protected from
ubiquitination in myoﬁbrils by its associated proteins. But because the
targeted proteins normally stabilize the myosin-containing thick-
ﬁlament, their selective ubiquitinationmay facilitate thick-ﬁlament dis-
assembly (the ﬁlament components are decreased by a mechanism not
requiringMuRF). Others agree that duringmuscle atrophy, thick (myo-
sin) ﬁlaments, but not thin (actin) ﬁlaments, are degraded by MuRF1
(muscle RING-ﬁnger1)-dependent ubiquitination [38,43,44,46–48,50,
52,53].
10.5. FoxO signaling
This coordinates activation of both the proteasome and autophagy-ly-
sosome catabolic pathways by FoxO3, a transcription factor that pro-
duces rapid loss of muscle mass with disuse, and systemically with
fasting, cancer, and many other diseases, due to its causing overall
accelerated breakdown of muscle proteins [38,43,44,46–48,50,52,53].
Activation of the transcription factor FoxO3 is essential for muscle atro-
phy, which occurs via transcription of a set of the atrophy-related
atrogenes, including critical ubiquitin ligases, as well as autophagy-
related genes. FoxO3 coordinately activates both proteolytic systems,
but especially the autophagy-lysosomal proteolysis. Activated FoxO3
stimulates autophagy through a transcription-dependent mechanism,
and increases transcription of many autophagy-related genes, which
are also induced in mouse muscle atrophying due to denervation or
fasting. In atrophyingmuscle, decreased IGF1-PI3K-Akt signaling stimu-
lates autophagy not only through TOR, but also more slowly by FoxO3-
dependent transcription, thereby coordinating regulation of protea-
some and lysosome systems. Elevated PGC-1-alpha or PGC-1-betaprevented the accelerated proteolysis induced by starvation or by
FoxO3 transcription factors. In mousemuscle, they inhibited denervation
atrophy by preventing FoxO's induction of autophagy and autophagy-
speciﬁc ubiquitin ligases, and they decreased inhibition of ubiquitin li-
gase induction of transcription by NFkappaB. In myotubes, they caused
increased protein content and decreased overall protein degradation
without altering protein synthesis.
10.6. Are atrophying type-2/2B myoﬁbers “altruistically martyring”, or
being “victimized”?
The type-2ﬁbers, and especially the 2Bﬁbers,more readily atrophy in
a number of different clinical situations, but the reasons are not known.
In general, atrophying type-2 ﬁbers undergoing self-cannibalization can
be considered eithermartyrs or victims [16].
10.8.1Martyring Type-2/2B ﬁbers can be thought of as, survivalistically,
selﬂessly giving up their protein, especially their myoﬁbrillar protein, to
be broken-down into its component aminoacids, which then are utilized
byother cells that aremore essential for survival of thepatient or animal –
such as brain, liver, kidney, and blood cells – those myogenous
aminoacids are used a) via the alanine-shunt, for synthesis by the liver
into glucose that is circulated forwider utilization, or b) by other essential
organs, for building their own cellular peptides and proteins. This putative
mechanism occurs in states of hyponutrition, cachexia, and disuse, which
are often induced by a chronic illness such as cancer, renal, pulmonary,
cardiac or infectious disease [20]. Autophagy, through bulk degradation
of muscle-ﬁber protein and organelles by lysosomal enzymes, and the
proteasome activity, allow type-1 myoﬁbers, other non-muscle cells, and
the whole animal, to survive during starvation [38,43,44,46–48,50,52,53].
FoxO3 is necessary and sufﬁcient for the inductionof autophagy in skeletal
muscle. FoxO3 is said to control the transcription of autophagy-related
genes Bnip3 and LC3, viz. the aspect ofmuscle-atrophy in a cancer patient
sometimes attributed to a “remote effect” (e.g. dysimmune, or possibly
from increased circulating TNFα or other toxic cytokines).
10.6.1. Why do muscle ﬁbers have such an elaborate complex of self-
destructing molecular systems?
Is it only to provide rapid-response of “martyring-atrophy”? Most
important medically, can we safely prevent or reverse that crippling at-
rophy in ageing persons?
10.7. There is no sure pharmacological method of directly treating or
preventing human muscle atrophy of ageing (MAA). Ancillary methods
include
10.7.1. General systemic treatments
Very carefully seek all possibly-relevant treatable diseases, and treat
any identiﬁed correctable causative disorder (e.g. dysimmune aspect,
hyperparathyroidism [17], other endocrine disorder, or vitamin deﬁ-
ciency). Correct any hyponutrition. Exercise as much as possible.
Check for fatigue as an effect of the primary disorder, a coexisting treat-
able disorder, or a side-effect from a drug or other treatment.
10.7.2. Pharmacologic treatments to consider
The various drugs, in current and potential use, have side-effects that
must be respected. The drugs will not be detailed here, but ones previ-
ously used include: i) testosterone, other androgens; ii) growth hormone
(somatropin); iii) oral leucine, ± isoleucine and valine (all three are
branch-chain aminoacids); iv) anti-myostatins. For future therapeutics
also consider possible modiﬁcations of these: insulin-like growth fac-
tor-1 (IGF-1); JunB; a β-agonist [60,61]; d) follistatin.
10.8. Cancer cachexia and cachectic atrophy [53]
This impairs the patients' quality of life and response to anti-
neoplastic therapies, and reportedly accounts for at least 20% of deaths
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many cachectic patients a) are undernourished due to an anorectic de-
crease of food intake,which they often deny, and b) if examined careful-
ly they sometimes are found to have a neuropathy.
10.10.1 Toxic cytokines can be released into the circulation, provoked
by a cancer or other chronic disease. They might: i) have a direct toxic/
cachectic effect on muscle ﬁbers or on their motor innervation; and ii)
suppress the appetite. Cachectogenic toxic cytokines include TNFα and in-
terleukins 1β, 6 8, 12, and 23, and they can be released by neoplastic cells,
macrophages, and adipocytes. Leptin released by adipocytes is appetite-
suppressing, and adiponectin is appetite-stimulating. Some of these fac-
tors in some test systems can be blocked by: an NFkappaB inhibitor
SN50; anti-TNFα drugs etanercept, inﬂiximab, and adalimumab; an anti-
cytokine-effect of thalidomide; and anti-IL12 and IL23 drug ustekinumab
(independently of a TNFα effect).
10.8.1. Treatment of cancer cachexia
Conceptually, this would be to attack the cachectogenic mediators
and protect their targets, while treating the cancer. These include: cyto-
kines and tumor-derived factors such as TNFα and their receptors;
androgen receptors; proteolytic pathways (ubiquitin-proteasome
and autophagy-lysosomal paths); intracellular signaling pathways
NFkappaB, AP1, FoxO, PKP; and the negative modulators of muscle
growth/hypertrophy (myostatin, GSK3-beta). In tumor-bearing mice,
there is marked muscle wasting and weight loss, associated with in-
creased p-ERK and decreased myosin heavy chain – this is prevented
by inhibition of ERK and return of atrogin-1 expression to normal. But
despite some beneﬁts to some experimental animals, there is no
established pharmacological treatment for cancer-cachectic patients.
Uncrtain is whether there might be a beneﬁcial role of existing, or fu-
ture, anti-TNFα drugs.
10.9. A pervasive “cachexia lente” hypothesis for ageing muscle
We hypothesize that there might be a “cachexia lente” in many, or
perhaps all, ageing persons (W.K. Engel – unpublished) due to various
additive combinations of hypoactivity, hyponutrition, and low-grade
systemic illness (dysimmune or other), ± known and undiscovered
cachectogenic cytokines, and other proposed atrogenic factors (v.s.). If
so, its facets might be therapeutic targets. But difﬁculties exercising to
achieve beneﬁt could be related to motivation, various pains, fatigue,
anorexia and the neuromuscular disorder itself.
10.12 Dolorogenic atrophy, v.i.
10.10. Myotoxic phenomena causing muscle atrophy of ageing are less
common
Somemyoﬁber atrophies are often assumed to be solely myopathic,
without any consideration that theymight actually be neurogenic (v.s.).
Actually, the toxins most likely directly myopathic are ones that cause
myoﬁber breakdown evidenced histochemically and by elevated
serum creatinekinase (CK) and myoglobin. Also, some affecting the
myoﬁber excitation-contraction mechanism, e.g. the periodic paralyses,
are considered deﬁnitelymyopathic. And, a number of genetic disorders
apparantly cause direct myoﬁber damage.
10.11. Glucocorticoid muscle atrophy (GMA)
Muscle biopsies of patients with glucocorticoid-induced muscle
weakness show what we identiﬁed as preferential atrophy of the
type-2 ﬁbers (the high-glycolytic, low-oxidative, fast-twitch ﬁbers)
(Fig. 2G) [16], and especially the 2B ﬁber subset.
In animal neuromuscular experiments, glucocorticoid is typically as-
sumed (perhaps not correctly) to act only directly on muscle ﬁbers to
cause the type-2 (more precisely, type2B) ﬁber atrophy. Hypothetically,
we consider it possible that glucocorticoid might cause concurrently, oreven mainly, a toxic motor-neuropathic mechanism contributing directly
to the type-2/2B atrophy. A putative corticosteroid neurotoxic effect
on LMNs could perhaps be: i) acting directly on LMNs, or ii)
susceptibilizing the muscle ﬁbers to a glucocorticoid neurotoxicity, or
iii) a glucocorticoid-provoked “relay neurotoxin” – if so, the latter
might, in principle, be akin to the experimental susceptilization, by
prior denervation, of muscle to chloroquine-induced toxic vacuolar
myopathy [62].
10.11.1. Glucocorticoid muscle atrophy biochemistry
IN GMA, Muscle proteolysis has the major role in the myo-
catabolism, especially involving the ubiquitin-proteasome system [38,
43,44,46–48,50,52,53]. It is mediated through increased expression of
several atrogenes, such as atrogen1 andMuRF1, which are two ubiquitin
ligases involved in targeting proteins to be degraded by the proteasome
machinery. Glucocorticoids are, according to some investigators, also
anti-anabolic, blunting muscle protein synthesis. Some aspects of the
glucocorticoid-induced atrophy might result from a demonstrated de-
creased production of IGF-1 and increased myostatin. IGF-1, by inhibi-
tion through the PI-3 kinase Akt pathway, antagonizes the myo-
catabolic action of glucocorticoid. Activity of the transcription factor
FoxO is a major activation switch for stimulation of several atrogenes
[38,43,44,46–48,50,52,53]. Glucocorticoid increases myostatin expres-
sion, and in mice myostatin gene-deletion prevents glucocorticoid-
induced muscle atrophy [38,43,44,46–48,50,52,53]. Glucocorticoid in-
creases mRNA of certain enzymes involved in proteolytic pathways
(atrogen1, muscle RING-ﬁnger1, and cathepsin-L), and it increases
chymotrypsin-like proteasomal activity.
10.14.1.1 Glucocorticoid- and sepsis-induced muscle wasting are both
associated with down-regulating expression of the nuclear cofactor
PGC1β in skeletal muscle, suggesting that this also contributes to the
muscle wasting. In glucocorticoid-linked muscle atrophy, as in several
other Type-2/2B myoﬁber atrophies, the myosin heavy-chain protein is
preferentially lost [38,43,44,46–48,50,52,53].
10.12. Examples of other extrinsic causative mechanisms or associations of
muscle atrophy in ageing
10.15.1 Hormonal abnormalities: high parathyroid-hormone
(Fig. 2H); low androgen; low growth-hormone; insulin resistance (e.g.
from high glucocorticoid, or genetic or possibly dysimmune); high
thyroid hormone; diabetes-2 dysimmune and genetico-diabetoid-2
dysimmune neuropathic mechanisms; possibly high parathyroid-
related-protein (sometimes released from tumor cells).
10.12.1. Abnormal immune complexes and/or toxic antibodies
10.15.2.1 In dermatomyositiswehave described presumably-toxic im-
mune complexes deposited in small blood vessels of muscle, typically as-
sociated with perifascicular atrophy of muscle ﬁbers (meaning the
atrophic muscle ﬁbers are located at the periphery of the fascicles of
muscleﬁbers) [63,64]– that pattern of atrophymight be due to ischemia
or vascular stagnation caused by the vascular deposition of immune-com-
plexes [63,64] (v.i.).
10.12.1.1. Myasthenia gravis (MG) v.i. 10.15.2.3 Circulating toxic auto-an-
tibodies, some of which, hypothetically, could be neuropathic, and result in
type-2 ﬁber atrophy in dysimmune neuropathies, which are more often
dysschwannian than dysneuronal type.
10.13. Other aspects of preferential type 2/2B ﬁber atrophy or hypotrophy
10.16.1 “Dolorogenic atrophy: pain, local, regional, or general in experi-
mental animals, and possibly in patients (e.g. in painful arthritic condi-
tions), seems to cause a sub-acute pain-reﬂex-atrophy beyond an effect
of any concurrent dolorogenic hypoactivity – a reﬂex dysinnervation or
a vascular phenomenon might be a causative mechanism.
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This is a phenomenon that slightly hypotrophies type-2/2B ﬁbers
because, conversely to a man, the average young adult woman has
type-2/2B ﬁber-diameters smaller than the type-1 ﬁbers. (In black-
widow spiders, we do not know the gender-speciﬁc diameters of
muscle-ﬁbers; the female is much larger and, appreciatively, eats the
male right after copulation [hence her name] ).
10.16.3 Prion or prionoid proteins, circulating “pre-amyloid” (v.i.), and
other misfolded and abnormally sticky or otherwise misbehaving proteins,
originating intracellularly, or extracellularly, seem capable of disrupting
normal cellular function and produce muscle-ﬁber atrophy, through
disturbing LMN inﬂuences (or perhaps by direct impairing myoﬁbers,
junctionally or elsewhere).
11. Ageing-muscle histochemistry: mitochondrial
pattern abnormalities
11.1. Absence, or prominent decrease, of cytochrome oxidase (COX) stain-
ing at a given transverse level of a muscle ﬁber (Fig. 3B), ± multifocal ab-
sences of COX distributed segmentally along the length of individual
muscle ﬁbers, as an aspect of ageing
These multiple foci, as shown Oldfors [65], indicate mitochondrial
abnormality. We propose they might be only the tip of the iceberg, sug-
gesting the possibility of an accompanying, crippling histochemically-
unapparent partial reduction or absence of COX in a percentage of the
muscle-ﬁber's multitudinous mitochondria. Because type-2 ﬁbers, and
especially 2B ﬁbers, normally have considerably less COX activity (and
perhaps less “COX reserve”), hypothetically they might be more likely
to atrophy from a partial impairment of COX activity. The speciﬁc path-
ogenesis ofmultifocal COX deﬁciency and othermitochondrial abnormal-
ities in elderly-aged muscle-ﬁbers is unknown.
11.2. “Increase-decrease ﬁbers”, “cauliﬂower ﬁbers”, “one-way streaks”
(Fig. 3C–F)
These “mitochondria-pattern abnormalities” are based on disar-
rangements of the normal orderly array of mitochondria in a delicate
network-like pattern amongst the myoﬁbrils. The pattern abnormali-
ties, reﬂecting myoﬁbrillar abnormality ± mitochondrial abnormality,
are seen more often in elder-muscle. Their exact pathogenesis, or path-
ogeneses, is uncertain. Focal increases of mitochondrial stainings in
myoﬁbers could be caused by: mitochondrial proliferation, decreased
turnover (mitophagy), or loss of interposing subcellular structures
(e.g.myoﬁbrils).
11.3. “Ragged-Red” ﬁbers (RRFs) (Fig. 3A) and “Rugged-Red” ﬁbers (RuFs)
In both of these, the accumulations of abnormal mitochondria are
bright redwith the Engel trichrome [16,66,67], and theirmitochondriality
can be demonstrated histochemically by positive staining with some of
these: succinate dehydrogenase, cytochrome oxidase, β-hydroxybutyrate
dehydrogenase or menadione mediated α-glycerophosphate dehydroge-
nase. Sometimes those mitochondria are deﬁcient in one mitochondrial
enzyme accompanied by an increased amount of another – histochem-
istry could detect this if the phenomenon would affect groups of
mitochondria, but not if it would affect only scattered individual
mitochondria.
11.3.1. “Ragged-Red” and “Rugged-Red” ﬁbers' overall structure
The ragged-red ﬁbers appear abnormally loose, while the rugged-red
ﬁbers have a ﬁrm, fully-packed appearance. Molecular-genetic analyses
in special laboratories can sometimes identify an exact mitochondrial
defect of RRFs [67]. These mitochondrial accumulations are often, but
not always, more in type-1 ﬁbers (which normally have more mito-
chondria). Clinically, the muscles with ragged-red ﬁbers are typicallyweak and more fatigable. The rugged-red ﬁbers are a presumably-
normal variation, apparently induced by heavy work [16,17 and
W.K. Engel unpublished]. With our trichrome stain they have a
bright red rim of packed mitochondria in most of the type-1 ﬁbers,
and clinically their muscles are very strong. They can be seen inmus-
cles of some persons doing very vigorous prolonged endurance
exercising, such as the quadriceps and gastrocnemius of frequent
long-distance cyclists.
11.4. Mitochondrial myopathies
These supposedly “primary” defects of muscle mitochondria (±
other cells) can be found by muscle biopsy. Histochemically there are
often ragged-red ﬁbers, ± some ﬁbers with either absent or excessive
stainingwith COX or SDH. There are various known biochemical defects
manifested as different clinical syndromes [67, and others].
11.5. “Noxious neighborhood” (NN) causing secondary mitochondriopathy
This hypothetical pathogenesis we proposemight occur in an unrec-
ognized “Noxious Neighborhood” viz., within muscle ﬁbers an abnormal
milieu that adversely affects mitochondrial function – for example, in-
volving a defective glycolytic, or another non-mitochondrial function,
v.i. [16,68]. Thus,“Things one sees are not always what at ﬁrst they seem
to be.” Two speciﬁc examples are:
11.5.1. In adult-onsetmuscle phosphorylase deﬁciency there are prominent
histochemically-evident probably-secondary mitochondrial disturbances
[68]
An example is our patient, the ﬁrst case, with clinical onset of fatigue
and weakness at age 48. Her muscle biopsy showed: a) complete ab-
sence of muscle-ﬁber phosphorylase, and b) prominent non-speciﬁc
patchy absence of mitochondrial oxidative enzyme activity histochem-
ically (Fig. 3D).Wenowhypothesize [16&W.K. Engel unpublished] that
the mitochondria were secondarily impaired due to lack of ATP conse-
quent to defective anaerobic glycolysis (a noxious neighborhood)
caused by the myophosphorylase deﬁciency. By analogy, possibly
any still-mysterious mitochondrial-abnormality might actually be
secondary to an unidentiﬁed glycolytic or other non-mitochondrial bio-
chemical abnormality (W.K. Engel unpublished).
11.5.2 Sporadic inclusion-body myositis (sIBM). This is another exam-
ple of probable-secondary mitochondriopathy [55,69–71 and Askanas
et al. chapter this issue]. In sIBM the Askanas team has found impaired
mitophagy [70,72] associated with intracellular amyloid-β oligomers
(noxious neighbors), and with amyloid deposits, which are the earliest
identiﬁable pathogenic steps. Those oligomers were considered to be
toxic to mitochondria because their over-expression within cultured
human muscle ﬁbers produced mitochondrial abnormalities (see
Askanas et al. chapter this issue). In sIBM they also found impaired pro-
teasome and autophagosomal-lysosomal functions, also possibly conse-
quent to toxic oligomers [70,72].
12. Therapeutic principles
12.1. N-of-1 + 1 + 1 studies
In our opinion, controlled trials involving many patients, seeking a
subtle beneﬁcial effect, are sometimes helpful but are not the sine qua
non providing all the information important for clinical management
[17]. Also, they can be very expensive, often seeming to be satisﬁed
with an inﬁnitesimally small beneﬁt that requires special statistics to
be demonstrated, but enough to be approved for marketing.
A number of “N-of-1” therapeutic experiences involving carefully-
monitored individual patients often can be very informative and clinically-
relevant. A few lucky and enduring therapeutic successes illustrate that
principle (v.i.).
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Clinicians understand that an intelligent and observant patient can
detect very subtle, but signiﬁcant, good or bad changes in motor and
sensory phenomena – such as fatigue, weakness, imbalance, numbness
and pain aspects– before the clinical exam or special machines can.
12.3 Usually not reliable enough, not reproducible enough, not subtle
enough – for monitoring results of treatment are sequential nerve-
conductions, electromyography, and muscle biopsies, although some-
times a repeat study is necessary to help clarify the pathologic process.
12.4 Sometimes general “Clinical Guidelines” are too restrictive, even
though originally intended to be helpful for patient-management: "Ab-
sence of a Guidelines beneﬁt is not absence of relevant beneﬁt, and presence
of a non-Guidelines beneﬁt is not irrelevant"
13. Other histochemical and clinical-pathologic changes in ageing
muscle ﬁbers
13.1. Increased triglyceride lipid droplets within muscle ﬁbers (Fig. 3H) can
signal a severe, but sometimes very treatable myopathy, e.g. muscle carni-
tine deﬁciency
Those droplets, which do not seem to be ageing-related, can result
from excessive circulating triglycerides, or from impairment of their ca-
tabolismwithin themuscle ﬁbers, including themitochondrial phase of
their utilization for ATP/energy fuel.
13.1.1 FourMuscle Carnitine Deﬁciency patients with excess lipid drop-
lets within their muscle ﬁbers, evident by histochemistry and electron-
microscopy, we have been treating similarly, utilizing:
13.1.2 Our therapeutic diet nearly devoid of long-chain fatty acids [16,
73–75] – A Spanish boy had progressively severe muscle weakness of
proximal limbs, swallowing, and breathing, which evolved to respirator-
and feeding-tube dependencyby age 17. Hewas slightly obese, very intel-
ligent and highly motivated. He loved to eat paella, but afterwards he
would feel weaker. He had failed carnitine treatment. (Carnitine is
needed for transporting long-chain fatty-acids (LCFAs) across the
inner mitochondrial membrane for metabolism, but it is not needed
for mitochondria to import short- and medium-chain FAs.)
13.1.3 ““Endodissolution” our then-new hypothesis, inspired by his
muscle-biopsy ﬁndings, was that the LCFAs accumulating within his
muscle ﬁbers were “endotoxic”, by forming micelles with sodium and
that these had a detergent action solubilizing cellular membranes, a
pathologic process we designated as an “endodissolution” (not an
“afuelia”). Our unique treatment, begun in 1981, was to de-fat him by
eliminating LCFAs from the diet, replace nutrition with multi-
component Portagen (Mead-Johnson Co.), whose lipid is only short-
and medium-chain FAs (from coconut oil), and also eliminate obesity
(initially with a diet of only 700 calories/d). Within 3 weeks he was
off the respirator and feeding tube, and walking a few steps, at 2.5
months he was walking 2.5 km/d, and in one year he was golﬁng.
Now, 33 years later, he maintains normal strength per our examination
in July 2014, is a busy international professional, a vigorous walker of
long distances, and remains on the unique diet (Engel & Askanas,
2014,unpublished).
(ii) That same long-chain fatty-acid-free diet was also successful in
treating three members of another family who had lifelong weakness
and fatty-food intolerance due to their autosomal-dominant lipid
neuromyopathy (which had excess lipid within muscle ﬁbers and
Schwann cells) and normal levels of muscle carnitine [76].
13.2. Lysosomal acid-phosphatase (acptse) staining
Histochemically, the major amount of enzymatically-active AcPtse is
associated with accumulations of lipofuscin granules, typically located at
the periphery ofmuscle ﬁbers (Fig. 3I). There is also a delicatemultipunctate
distribution of AcPtse (without histochemically-discernable lipofuscingranules) throughout the muscle-ﬁber cytoplasm. AcPtse at both sites in-
creases with ageing in everyone, the quantitative amount varying from per-
son to person. It is not established whether the gradual increase of those
lysosomes is beneﬁcial, detrimental, or neutral. It could a signal that
various other, currently-invisible and possibly toxic,molecules might also be
gradually accumulating in that ageing muscle ﬁber. The lipofuscin itself
seems to be indigestible cellular detritus, accumulations of which persist
even in very atrophic denervated muscle ﬁbers (see Lysosomal Vacuolar
Myopathies, v.i.) (W.K. Engel, unpublished).
13.2.1. Lysosomal vacuolar myopathies
These membranous vacuoles seem to be enlarged lysosomes unable
to adequately digest certain intracellular detritus. Examples are:
13.2.1.1 Sporadic Inclusion-Body Myositis (sIBM), is a "degenerative"
vacuolarmyopathywithmulti-protein aggregates (inclusions), including
aggregates containing amyloid-β, phosphorylated-tau, α-synuclein,
parkin and at least a dozen other “Alzheimer-type” and “Parkinson-
type” proteins in those accumulations [55,69–71]. Probably most of
those aggregates are stained by the ﬂuorescent Congo-Red method of
Askanas [6], indicating misfolded proteins in beta-pleated sheet “amy-
loid” conﬁguration. sIBM has proven abnormalities of proteasomemetab-
olism and of autophagy/lysosomal-mitophagy [55,69–71]. sIBM also has a
lymphocytic "inﬂammatory" component, but the patients do not re-
spond deﬁnitively to immunosuppression, suggesting a greater impor-
tance of the sIBM degenerative component, which remains untreatable
(see Askanas et al. chapter this issue).
13.2.1.2Hereditary Inclusion-BodyMyopathy (hIBM) (77, 78; also see
Broccolini and Mirabella chapter, this issue). hIBM has vacuoles, and
can have similar but fewer intra-myoﬁber cytoplasmic congophyllic
amyloidic inclusions containing amyloid-B or phosphorylated-tau. hIBM
is caused by an autosomal recessive mutation of the GNE or VCP gene
[77,78].
13.2.1.1. Adult-onset acid-maltase deﬁciency (AMD). Usually AMD is of
childhood onset, but sometimes it appears in adulthood as a proximal
muscle weakness. It progresses slowly and thus can be present in an
older person. Multi-vacuolated ﬁbers are typical, but they are not al-
ways detected with only one biopsy of one limb. It is not associated
with amyloid inclusions. Enzyme-replacement therapy by others is
showing some beneﬁt.
13.3. T-tubule vacuoles, periodic paralyses, acetazolamide
The vacuoles are typical of hypokalemic periodic paralysis. When
present they are usually one per cross-sectioned myoﬁber. Therapeuti-
cally, in hypokalemic periodic paralysiswe initially introduced acetazol-
amide and achieved excellent beneﬁt [79,80]. Then in both hypo- and
hyperkalemic periodic paralyses, dichlorphenamide (which we chose be-
cause it is also a carbonic-anhydrase inhibitor) was introduced and
proved very beneﬁcial, even in some patients not responsive to acet-
azolamide [81]. These two drugs, initially and in maintenance, promi-
nently reduced frequency and severity of the paralyzing-attacks, and
they increased inter-ictal strength. They have become useful and ac-
cepted therapy.
13.4. Tubular aggregates (TAs)
These are collections within muscle ﬁbers of proliferated tubular
lateral-sac/longitudinal reticulum membranes, bright-red with the
Engel trichrome, present only in type-2 ﬁbers [82]. Like mitochondria,
they stain darkly with the NADH-TR reaction, but unlike them the TAs
do not stain with the mitochondria-speciﬁc reactions of cytochrome
oxidase, succinate dehydrogenase, and menadione-mediated α-
glycerophosphate dehydrogenase. Electronmicroscopy displayed their
ultrastructure, which we named. They have been found in some patients
with atypical periodic paralysis, some taking large amount of pain
Fig. 4.Dysimmune sensory-motor peripheral neuropathy in a type-2 diabetes patient, age
66. The orange-stained calcium is prominently deposited in the perineurium of nerve-
twigs, in a submitted sural (sensory) nerve biopsy. ×1250.
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(V Askanas and W.K. Engel, unpublished), in which they are sometimes
misinterpreted – TA's are not a feature of human elderly muscle.
14. Deﬁciency examples in ageing, known and hypothesized
These can be (i) endogenous (e.g. dysimmune; cellular “wearing-out”
(“post–warranty”), inadequate absorption or utilization of a critical sub-
stance, or (ii) i) exogenous (e.g. dietary).
14.1. Known, subacute combined degeneration (SACD) of the spinal cord,
peripheral-nerve and brain, responive to subcuaneous B12
In SACD, theduodenum is unable to absorb vitamin B12 due to lack of
the essential “intrinsic factor” caused by an ageing-based autoimmune at-
tack on the gastric parietal cells, which should, but cannot, be producing
the intrinsic factor required for B12 absorption. The formerly crippling,
and sometimes dementing, disease SACD, and its associated megalo-
blastic anemia are now readily treatable with B12 (cyanocobalamin) at
home by using an insulin syringe for 1-mg subcutaneous self-injections
on a schedule of 7,3, or 1 x/week, without signiﬁcant side-effects [see
[16,17 and W.K. Engel – unpublished]).
14.2. Known, severe genetic methylenetetrahydrofolate reductase deﬁcien-
cy, responsive to beatine
This is a different aberration of the B12-metabolism system, which
causes an hereditary CNS disorder, Adult-Onset Hereditary Spastic Para-
plegia, with coticospinal tract degeneration and peripheral neuropathy,
and various CNS abnormalities [83]. The patients have severe hyperho-
mocysteinemia and hypomethioninemia – importantly, they respond to
betaine therapy. This phenomenon somewhat enhances the possibility
that another variation in the B12 metabolism system might have a role
in pathogenesis of some ALS patients.
14.3. Hypothesized: amyotrophic lateral sclerosis, sporadic and hereditary
(sALS, hALS)
Wehave suggested that a complex pathogenicmechanism similar to
that of SACD – our XYZ hypothesis of a virus or other microbe initiating a
dysimmune deﬁciency, or toxicity – might be a treatable cause of ALS
[84–89]. If so, perhaps a very simple therapeutic molecule might be-
come as effective and available as B12. In hypotheses regarding ALS,
we have also considered a possible role of: a) abnormal juxta-neuronal
astrocytes (possibly neuronal nurturing cells) in the neighborhood of
motor neurons [88]; b) the ALS gut and its ﬂora or fauna (the
microbiotome); c) the ALS liver; d) Q-fever; and e) the presumably-
essential high phosphorylase and glycogen, and low mitochondrial SDH,
we found in normal cat LMNs [85,86,88–91]. Yet despite much work,
and various therapeutic trials, the pathogenic and therapeutic identiﬁ-
cations have not yet been derived from the numerous ALS studies by
many others and ourselves – nor from analyses by others of mutations
of the autosomal-dominant hALS forms and of putative genetic predis-
positions in sporadic forms (see Ajroud-Driss and Siddique T, chapter
this issue).
14.4. Spinal-cord possible clues to ALS pathogenesis
Potential pathologic clues [84-91] are, in typical cases: a) suggesting
a diffuse deﬁciency or toxicity in ALS, (i) identical patterns of demyelin-
ation in the middle-root zone (MRZ) of the posterior columns in B12-de-
ﬁcient SACD, and in some cases of clinically-typical, autosomal-
dominant hALS; and (ii) in sALS and hALS, the entire lateral and anterior
columns ofwhitematter aremoderately pale (demyelinated), indicating
involvement more than the very pale corticospinal tracts, (contrastingwith the darkly-stained myelin of the normal-appearing posterior col-
umns); b) prominently increased oxidatively-stressed astrocytes (are
they assassins?), and macrophages [88] (co-assassins?) in the gray-
matter ventral horns and demyelinating regions.
15. Calcium, extracellular and intracellular
With the histochemical reaction for calcium, which we do on every
biopsy, we can see calcium abnormally deposited in various places.
15.1. Extracellular tissue calcium in blood vessels. Deposited extracellular
calciummay have a weakening or obstructing effect in larger blood vessels,
arterioles, and capillaries
15.1.1. In muscle capillaries, calcium increases with ageing
InDiabetes-2 andGenetico-Diabetoid-2 patients (v.i. Diabetes-2), this is
often higher than usual for the patient's age (W.K. Engel – unpublished).
15.2. Extracellular calcium in perimysial and endomysial connective tissue
Themost extreme and crippling example is “calcinosis universalis” as-
sociated with some patients, especially children, with dermatomyositis.
15.3. Intracellular myoﬁber calcium
Sometimes calcium accumulates within damaged myoﬁbers, where
in some myopathies a breeching of the plasmalemma allows inﬂow of
the normally higher calcium level, which then promotes focal or general
damage of the myoﬁber.
15.3.1 In Duchenne muscular dystrophy (DMD) myoﬁber breeching
damage might actually be provoked by a now-accepted ﬂuctuating
micro-arterial ischemia of muscle, which we ﬁrst suspected from the
histochemical pattern of multifocal groups of same-stage myoﬁber ne-
crosis or same-stage myoﬁber regeneration [92–95]. Our derived hy-
pothesis of a pathogenic vasculopathy component of the dystrophin-
mutated DMD has led to therapeutic trials, by others, of PDE5 inhibitors.
Tadalaﬁl/Cialis [96] was seen to improve blood-ﬂow to the exercised
DMD muscle; sildenaﬁl/Viagra, has also been considered somewhat
helpful in other studies. Perhaps a drug more speciﬁcally dilating
muscle.
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perineurium
The ageing-related gradually increasing perineurium calciﬁcation
(Fig. 4), which we have noted in submitted sural (sensory) nerve diag-
nostic biopsies of sensory-neuropathy patients, is evident from about
age 20-30 upward (W.K. Engel – unpublished). Enigmatic is whether
thismight be amarker of a contributing cause, e.g. amarker of abnormal
transport across the perineurium blood-nerve barrier, and whether it
might play a role in some ageing-related peripheral neuropathies.
15.5. Calcium within macrophages
Either scattered or in groups,when related to damagedmuscleﬁbers
themacrophages , pan-esterase and acid-phosphatase positive,virtually
always contain excess calcium, whichmight be bound to ingestedmyoﬁber
detritus (W.K. Engel – unpublished).
16. Amyloid, extracellular and intracellular
16.1 “Amyloid” is an aggregation of misfolded proteins in beta-
pleated sheet conﬁguration. In skeletal muscle, tissue amyloid can be:
a) extracellular, usually in muscle connective tissue regions and in the
walls of small blood-vessels, and also in blood-vessels of peripheral
nerves; or b) intracellular, within muscle ﬁbers of sIBM (v.s.)
[55,69–71]. Various proteins can become misfolded and aggregate
homologously into β-pleated sheet-amyloid, ± become “sticky-bonded”
with other proteins as multiprotein aggregates (ibid). All amyloid aggre-
gations are stainable with the ﬂuorescence congo-red method of
Askanas, or more simply but less inclusively with crystal violet. A new
rapid technique from Sweden utilizes compound LCO, but is not yet
commercially available.
16.2 In both extracellular and intracellular amyloid pathogenesis, we
think it more likely that the clinically-evident cellular impairment is
caused, not by the small space-occupying amyloid deposits, e.g. extra-
cellularly in small blood vessels and perimysial connective tissue, but rath-
er by submicroscopic amyloid-precursor molecules (oligomers),which had
become misfolded and “sticky” and thereby molecularly cytotoxic [16,97].
Possibly such amyloid-precursors, when they are extra-cellular, might
have a cytotoxic inﬂuence plasmalemmaly or even trans-plasmalemmaly
to impair intracellular machinery.
16.1. Muscle and peripheral-nerve extracellular amyloid
This is often composed of: (i) the variable portion of immunoglobulin
light-chains, or (ii)mutant transthyretin.
17. Dysimmune neuromuscular disorders – a brief summary of
pathogenesis-based treatments
17.1 Our principles of anti-dysimmune treatment, within the limits of
safety and side-effects are [16,17]:
a) Stop the pathogenic damaging as soon and as effectively as possible,
and
b) Permit maximal endogenous cellular molecular repair-regeneration.
c) Rationale: "The longer cells remain malfunctioning, the greater like-
lihood they will die":
NORMAL←→MALFUNCTIONING-BUT-ALIVE→ DEAD
17.2. Individualize anti-dysimmune treatments
17.3Maximally limit cellular malfunction as effectively as possible, to
prevent ingravescent irreversibility that results in cell death
17.4 It ismedically inappropriate for a physician to choose intentionally
to provide less than optimal anti-pathogenic therapy of a dysimmunedisease, or be satisﬁed with clearly less than possible optimal improvement
(and also incorrect for insurances, HMO's, or a government to do so con-
trary to good medical care).
That would be similar to intentionally suboptimal treatment of in-
fectious diseases, which is clearly inappropriate.
17.5 Achievemaximally-summated improvements, based on clinically-
evident cellular-repair vis-à-vis clinical expectation, for example when
using IVIG (intravenous immunoglobulin G).
17.6 Be not content with a less-than-optimal plateau of blunted
improvement, nor with repeatedly-unsustained, unsummating little
improvements – one should treat maximally and often enough to pre-
vent “Sisyphusian Futility”.
17.6 Sisyphusian Futility [16,17]. In Greek mythology, Sisyphus was a
misbehaving character, punished by the gods by being compelled to
roll an immense boulder up a steep hill – but each time, before he
could keep it at the top of the hill, the huge rock would always roll
back down, forcing him to begin again, and again, and again, repeating
this endless toil throughout eternity, and beyond. Repeated IVIG treat-
ments given in sub-optimal doses and frequency typically fail to
produce maximally summated cellular recovery for optimal beneﬁt,
resulting in Sisyphusian futility for the patient, and physician. This
should be avoided if at all possible. In our experience, the IVIG optimal
beneﬁt usually lasts only 1-2 weeks after the last infusion, sometimes
even a shorter time – thus, reappearance of symptoms before the next
dose indicates a Sisyphusian inadequate-frequency, a major hindrance to
long-term cellular summated and sustained beneﬁt, and possibly
ingravescently adding to an irreversibility of the cellular damage the phy-
sician is attempting to repair.
17.6.1 The oft-quoted half-life of circulating IgG is misleadingly longer
(v.i.) than the more important duration of maximal clinical beneﬁt,
which an observant patient can more correctly precise (including levels
of pain and numbness, fatigue, endurance and weakness). (But we also
emphasize that individual IVIG doses given in too-large amounts and/or
too rapidly in an infusion session can be risky, occasionally producing
generally-unwell feeling, hypertension, headache, or blood-vessel
blockage.) Infused IVIG thickens the blood, and so one can give aspirin
before IVIG infusions (unless coumadin or clopidogrel is already being
taken).
17.7 Future: Consider developing new drugs that can enhance cellular
repair and regeneration (without enhancing neoplasia) in the central
and peripheral nervous system, to be given concurrentlywith improved
anti-pathogenic (e.g., anti-dysimmune) drugs, such as improved IVIG.
18. Schwann-cell malfunctions→ neuronal-axon malfunctions→
clinical symptoms
Schwann-cell rapidly-reversible→ slowly-reversible→ irreversible-
abnormal-moments,… and consequently→ neuronal-axon-reversible
→ neuronal-irreversible-abnormal-moments.
and consequently→ neuronal-axon-reversible→ irreversible-ab-
normal-moment. In a Dysschwannian Neuropathy, including Acute
Immune Dysschwannian Polyneuropathy (AIDP) Guillian-Barré and
Chronic Immune Dysschwannian Polyneuropathy (CIDP), the basic
malfunction of Schwann Cellswill cause symptoms only by their fail-
ing to adequately comfort and nourish their lower motor or sensory
neuronal axons.
18.1. Proposed overlapping phases of therapeutic anti-dysimmune cellular
improvement, with timings that seem to occur during the IVIG-induced im-
provement of cellular damage in CIDP [16,17,98–100]
a) RAPID: 1-14 days = Reversing of “Moment-to-Moment Molecular
Inhibitors”, such as the cytotoxic action (e.g. cytotoxic-afﬁnity) of
pathologic immunoglobulins, cytokines, T-cells, macrophages or
other damaging agents, including putatively pathogenic misfolded
proteins.
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Mechanisms of Schwann Cells, Neurons and Muscle Fibers.
19. Brief comments on some neuromuscular
anti-dysimmune treatments
19.1. Glucocorticoid
In diabetics or patients with a close family history of type-2 dia-
betes (D2), we try to avoid glucocorticoid treatment, which can ag-
gravate or bring-out D2. In non-diabetic patients, when we do use
a glucocorticoid, usually prednisone, we prefer: single-dose alternate-
day, before 8 am, prohibit caffeine/stimulants, restrict sodium, and sup-
plement potassium.
Future consideration: modify the prednisone molecule to keep the
beneﬁcial motif and eliminate the side-effects motif.
19.2. Rituximab is a rapidly-acting immunosuppressant toxic to CD20
B-lymphocytes, small subsets/clones of which are the main pathogenic
elements in a number of dysimmune diseases. Intravenous infusions
of rituximab are closely supervised. (Not yet established is whether or
not there will be any long-term toxicity of chronic rituximab treatment
of severely-affected dysimmune neuromuscular patients, whose dis-
ease itself might not be life-shortening.) Until now, rituximab has only
rarely caused progressive multifocal leucoencephalopathy, a severe JC-
polyomavirus disease of the brain. One must monitor closely for side-,
e.g. neutropenia and anemia.
Commonly, each daily i.v. rituximab dose is 375 mg/m2 (or split on
two adjacent days, per S. Forman) , initially given weekly for 3-4
doses, and then the four-week-cycle is repeated every sixmonths. How-
ever, we are following one sensory N motor CIDP, carefully monitored
patient, with a serum IgM-monoclonal and quantitatively elevated
IgM and MAG-antibody who, per another physician, has been having a
good rituximab response for ﬁve years, but his symptoms begin to re-
turn about 2 months before his next 6-monthly dosage is due. This
Too-infrequent dosing potentially invites Sisyphus relapses, and possi-
bly ingravescent irreversibilities, whereas too-frequent dosing might
jeopardize the bone-marrow. We recently developed, for a patient
with dysimmune adult-onset rod-myopathy syndrome plus a CIDP-aspect,
with monoclonal gammopathy [17,101], what seems to be a better ritux-
imab schedule to follow after the induction course of four weekly doses
– it consists of a once every 4-weeks “maintenance-dose” (developed
with Drs. N. Gupta and I. Luthra). The patient had further improvement
for about six months, but then the insurance company sopped
supporting this effective treatment.
c. New Drugs. Consider using for dysimmune diseases new anti-
lymphocyte drugs, such as ones that look promising for chronic lym-
phocytic diseases. One currently showing early usefulness for B-
lymphocyte malignancies is Ibrutinib, an inhibitor of Bruton's tyrosine
kinase [102,103].
19.3. Abolish the “WBC”
Circulating “white blood cells”were identiﬁed concurrently by Andral
and Addison in 1843, and the total “wbc” entered clinical medicine.
Now, 171 years later, the two major wbc components, neutrophils and
lymphocytes, are well-established as are their quite different biological
properties and clinical signiﬁcances. It is archaic, irrational and
befogging to view these “apples and oranges” as one number, the
“wbc” – and it is past time to abolish the “wbc”. “What’s the white
count” still rings through the halls of academia and community hospi-
tals, from students to residents to venerated professors, even hematolo-
gists. Ubiquitous are “wbc”, “leukopenia” and “leukocytosis” expressed
inanely in FDA-approved drug package-inserts and tons of medical
tomes. Automation quickly provides a crisp differential of thewbc com-
ponents, as are absolute numbers of neutrophils and lymphocytesneeded to interpret their signiﬁcance. Change of one can mask normal-
ity or abnormality of the other – for example, during an anti-
dysimmune treatment a “low wbc” due to low lymphocytes and normal
neutrophils is actually a therapeutic desire, not a reason to interrupt a
successful treatment. We should receive, and teach, only absolute
counts.20. Other dysimmune neuromuscular disorders with then-new
successful treatments: brief comments
20.1. CIDP
This is the most frequent chronic or subacute adult neuromuscular
disease we see. It can be mainly motor, or sensory, or mixed. It occurs
more often over age 30, and often it is highly treatable. It seems to in-
clude a higher than expected number of persons with diabetes D2, or
ones having a ﬁrst-degree relative with D2 (v.i.) [16 and W.K. Engel –
unpublished]. For a sensory component, routine nerve-conduction ve-
locity (NCV) tests, which measure only the fastest-conducting large-
diameter nerve ﬁbers, can miss seeing abnormality of the normally-
slower pain-conducting ﬁbers (and excess or reduced pain sensation
is often a major symptom). Thus a normal sensory NCV test cannot be
interpreted as the patient having completely normal sensory-nerve
functions. (And EMG might miss type-2 ﬁber abnormality.)20.2. Intravenous immunoglobulin (IVIG) treatment of CIDP
In dysimmune diseases, IVIG treatments are the best and safest for pro-
moting cellular healing [104,105]. Whereas prednisone ± azathioprine,
or rituximab can sometimes produce such healing, to a lesser degree,
each can have rather signiﬁcant side-effects. An only-symptomatic
treatment for CIDP (e.g. for pain or cramps) does nothing to stop and re-
verse the cyto-molecular destruction that continues to worsen. Far bet-
ter for the patient is to try to promote cellular healing of the dysimmune
disorder. In our experience, there are three broad therapeutic actions of
IVIG: anti-dysimmune, anti-bacterial, and anti-viral [106].20.2.1. IVIG might help Ebola patients
In our experience, there are three broad therapeutic actions of IVIG:
anti-dysimmune, anti-bacterial, and anti-viral [106]. For these reasons,
we have proposed IVIG for treatment, and prevention, of the deadly
Ebola virus-infected victims, starting with treating the dangerously ex-
posed health-care workers at the ﬁrst clinical hint of infection or posi-
tive blood test.20.2.2. Half-life of IVIG beneﬁt
The stated half-life of the administered IgG circulating in the blood
varies, e.g. 20, 35, and 18–32 days, but that is misleading clinically be-
cause it is not ameasure of the biological therapeutic half-life for the in-
dividual patient, nor does it consider the blood-level that must be
maintained to achieve persisting beneﬁt. For example, in one patient
we repeatedly documented that the necessary therapeutic blood level
of IgG was above 2200 (the laboratory-stated normal blood level of
IgG is 650-1650 mg/dL); below the 2200 level, his symptoms began to
reappear, in a Sisyphus roll-back relapse (W.K. Engel – unpublished).
For our patients, mostly with CIDP, the maximal IVIG-induced clini-
cal beneﬁt lasts only 5—10 days before going into a trough.Overall, indi-
vidual IVIG doses given more than 10 days apart seem likely to increase the
possibility of Sisyphus-type relapses, as do 5-consecutive-day groups of
doses given more than 3 weeks apart.
Note: "A pharmacological relapse is not a disease relapse" – but it
could be detrimental to the molecular structure of the reversibly-
damaged schwann-cells and neuronal-axons.
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Try to identify the active anti-dysimmune region of the IgGmolecule
and synthesize it for simpler, quicker and cheaper treatments.
20.2.4. Benign “pseudo-lupus” side-effects of IVIG
A few benign “pseudo-lupus” laboratory-parameter side-effects
from IVIG include: high sedimentation rate; positive circulating im-
mune complexes, rheumatoid factor, and anti-thyroid antibodies;
some positive lupus-panel tests; and various rashes. Because of these,
several of our patients were erroneously told, very disturbingly, by a
local physician, “You've got lupus” [107].
20.2.5. Brief summary of IVIG dosing and schedules
The IVIG dosage and schedulemust be individualized for each patient
[108,109].
The usual IVIG daily infusion dose is 0.4 g/kg. on ﬁve consecutive
days every third week [100,108,109]. (We infuse slowly, very conserva-
tively, generally not over 100 ml/hr, and slower for worrisome patients
who are considered susceptible to hypertension, headache, or vascular
occlusion, and for patients with a general frailty of ageing.) Although
some IVIG Package-Inserts (PI's) have condoned infusions up to 250–
340 ml/hr for a 70 kg patient, we consider that those high rates might
increase the risk of a thromboembolic vessel-blocking side-effect, espe-
cially in an elderly person.While some physicians give 2-2.5× our daily
amount in one day, or on two consecutive days, we consider that those
schedules might increase the risk of thromboembolic vessel blockage.
For worrisome patients, 17 years ago we invented an infusion schedule
of 0.4 g/kg on two non-consecutive days every week [100,108,109]. That
provides a more even elevation of IgG blood-levels and fewer side-
effects. More recently, we have sometimes utilized a schedule of 3-
week cycles of three infusions/week × 2 weeks and then a week off,
namely 3-3-0/week, the one no-infusion week being appreciated by
the patients. While these are my personal preferences based on closely
monitoring each IVIG-treated patient, others might have other opinions
(see review by Dalakas MC, this issue).
20.3. Dysimmune neuropathy in Type-2 diabetes (D2)
In D2 there can be an often-well-treatable Dysimmune (Di) Distal
Motor-Sensory Polyneuropathy (D2-DMSPN). In 1975 P.K. Thomas &Fig. 5.Diabetes-2 peripheral neuropathymechanisms. These three types of pathogenesis can
overlap to various degrees in individual diabetes-2 patients. See details in the text.S. Eliasson wrote: “The typical ﬁnding in the CSF of diabetic patients
with peripheral nerve involvement is a ‘moderate increase of the total
protein content’” [110], and quoted Bischoff (1963) [111] as having
found elevated CSF protein in 66% of 318 cases, with an average value
of 60 (upper normal 45). Thomas and Eliasson also stated “there are
protein levels of over 250 mg% in some very severe diabetic neuropa-
thies” (loc. cit.). They did not mention any dysimmune explanation or
any anti-dysimmune treatment. However, based on their diabetes
comment and our experience at that time treating high-CSF-protein
dysimmune neuropathies, we have since 1990 been ﬁnding thatmany
D2 patients, and also “genetico-diabetoid-2” patients (v.i.), have a
highly-treatable dysimmune “diabetic neuropathy” [16,112].
Currently, it appears that in D2 there are three general pathogeneses
operative in D2-DMSPN, and we consider all three as often overlapping
types of “diabetic peripheral neuropathy”: dysimmune, dysmetabolic,
and dysvascular (Fig. 5).
Our treatment has been very successful for N21 years, especially
with IVIG (before IVIG was available, we successfully used prednisone
in a few patients, but with the concern that prednisone can worsen
the D2 patient’s insulin resistance)[108,112]. Although not all D2 neu-
ropathy patients have an identiﬁed dysimmune aspect, among D2 neu-
ropathy patients referred to us as “diabetic neuropathy”, about 200
were dysimmune and none had peripheral vascular insufﬁciency or
skin ulceration (W.K. Engel- unpublished). It is true that the dysimmune
DMSPN in D2 patientswas essentially identical to CIDP in non-diabetics,
but that does not negate its possible dysimmune pathogensis being as-
sociated with the patients’ diabetic/diabetoid milieu. In our D2 patients,
there seemed to be,without detailed statistical analysis, a propensity for
this dysimmune form of DMSPN to occur. Moreover, there was a ten-
dency for ﬁrst-degree relatives of our dysimmune-D2 patients to have
D2 and/or a dysimmune neuropathy.
Still unknown is the immunologic reason that dysimmune
DMSPN occurs often in D2. We have proposed that the genetic
molecular milieu of diabetes-2, perhaps by providing a foreignized mo-
lecular antigen or target, possibly produced by a pathogenic advanced
glycation product or an abnormally-oxidized molecule, predisposes to
dysimmune neuropathy, by a mechanism possibly not related directly
to glucose dysmetabolism [16,17]. In our very IVIG-treatable
dysimmune D2 and D2oid diabetic neuropathy patients, the IVIG
does not have an obvious effect on their glucose dysmetabolism
(W.K. Engel – unpublished).
It is important to continue classifying the dysimmune neuropathy of D2
patients as an often- very-treatable form of “diabetic neuropathy”. Tomax-
imally help D2-DMSPN patients, the physician should diligently study
each one for evidence of a treatable dysimmune disorder, seeking
dysimmune parameters: in blood, e.g. immunoglobulins and monoclo-
nal antibodies; and also to be considered in every D2 DMSPN patient,
CSF studies for elevated protein, and IgG synthesis. And in nerve con-
ductions, seek dysschwannian slowing (some dysneuronal neuropa-
thies in D2 can also be dysimmune). If a dysimmune process seems
possible in the patient, IVIG treatment should be tried, per one of the
above-suggested schedules.20.3.1. “Genetico-diabetoid-2 dysimmune neuropathy” (GD2DyN)
This term we have been using for 25 years to describe a) the same
clinical and laboratory features as in the above-mentioned “diabetes-2
dysimmune neuropathy”, b) and that these in patients having a close
family history of diabetes-2 but who themselves do not yet have
detectable glucose dysmetabolism parameters indicative of actual
diabetes-2 [108]. In such patients, we ﬁnd that that their dysimmune
polyneuropathy can bemanifest as long as 10 years before their D2 glu-
cose dysmetabolism becomes evident. This GD2DyN is often very well-
treatable with IVIG [108].
Note: In a patient who has a close family history of diabetes-2, any
glucocorticoid should be avoided if possible (v.s.).
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neuropathy
Some authors explicitly or tacitly or dismiss the concept that a
dysimmune neuropathy may be related to an immunologic aspect of
the patient's type-2 diabetes. Accordingly, they seem to consider that
the Dysmetabolic/Dysvascular (Dysm/Dysv) Combined Form as the
only form of D2 neuropathy (this combination has variably overlapping
features in individual diabetic patients). Typically the Dysm/Dysv pa-
tients have major problems of glucose metabolism and peripheral vas-
cular disease, peripheral limb ulcers, and amputations necessitated by
peripheral ischemia [113], which our dysimmune paients do not have.
Even the American Diabetes Association website does not mention the
treatability of the dysimmune form of D2 when discussing “diabetic
neuropathy” – apparently that approach considers the dysimmune
form as a non-diabetic CIDP. The American Academy of Neurology
Guideline for treating “diabetic neuropathy” only discusses non-anti-
dysimmune approaches to neuropathic pain occurring in a diabetes pa-
tient. A difﬁculty is that many general physicians, and others, do not
make those clinical distinctions and, incorrectly, give to all D2 diabetics
who have a peripheral neuropathy, the following academic dire progno-
sis for “diabetic neuropathy”, stating: “Currently the only effective treat-
ments are glucose control and pain management” [113].
20.5. Myasthenia gravis (MG)
MG is caused by toxic auto-antibodies against the nicotinic receptor
at the post-synaptic part (muscle side) of the neuromuscular junction.
In every MG-patient's biopsied muscle (n N 200) we have found
muscle-ﬁber atrophy – recent denervation, type-2/2B ﬁber atrophy, or
both [114]. The cause of that atrophy is presumably post-synaptic, viz.
literally amyogenous deinnervation phenomenon [115] and likelymulti-
factorial, probably resulting from: i) impairment of trophic-factor trafﬁc
from the lower motor neuron (LMN) to the muscle ﬁber related to
anti-nicotinic antibody binding to and damaging the post-synaptic
part of the neuromuscular junction; ii) clinical muscle hypoactivity due
to weakness; and iii) in someMG patients a corticosteroid-atrophy com-
ponent from MG treatment. In addition, there is also some binding of
toxic auto-antibody to the pre-synaptic neural tips of the LMNs [116],
which probably causes an additional true neuropathic atrophy compo-
nent. At a time when prednisone for MG was being strongly discouraged
generally, its use in MG seemed logical to us, and we used it starting with
respirator-dependent patients and achieved excellent beneﬁt, having a
rapid and then a slower component. In 1970-71 we reported its efﬁcacy
for MG [117–120]. We prefer to give the prednisone without an often-
confusing concurrent anticholinesterase. Now prednisone is considered
standard acute and maintenance therapy applicable to many MG pa-
tients. Refractory MG patients often beneﬁt acutely from plasmaphere-
ses or from acute plus longer-term treatment with IVIG. Because a) MG
patients often have a lymphocytic thymoma (“thymitis”) and often bene-
ﬁt from a complete thymectomy, and b) normal human thymic epithelial
cells (TECs) have nicotinic receptors antigenically similar to those at the
NMJ [117], we have proposed that: MG might begin with a viral or
other infection of those TECs, and the resultant lymphocytic thymitis re-
sults in anti-TEC-nicotinic receptor antibodies which unfortunately
cross-react with nicotinic receptors at the NMJs to produce MG – thus
a Sparafucile misdirected assignation, like in Rigoletto [117].
20.6. Facilitating syndrome (of Lambert & Eaton)
This is a NMJ presynaptic disorder, occurring most often as a remote
effect of a carcinoma, especially a bronchogenic small-cell carcinoma. A
circulating toxic antibody binds on the presynaptic side of the NMJ to
the voltage-gated calcium channels. Clinically the syndrome has muscle
weakness, but the strength facilitates (improves) with repeated
voluntary or electrically-stimulated contractions. Anti-dysimmunetreatments are sometimes beneﬁcial. Anti-neoplasm treatment is ap-
propriate, but not necessarily beneﬁcial to the facilitating syndrome.
20.7. Refractory adult dermatomyositis/polymyositis (DM/PM) treated very
successfully with small-doses of total-body irradiation (TBI)
DM/PM, like other dysimmune diseases, is often successfully treated
with high-single-dose alternate-day prednisone, or with azathioprine,
rituximab, or IVIG, but some patients do not respond. Lymphocytes
are considered the major troublemakers in DM/PM (and in other
dysimmune diseases), and they are the most susceptible of circulating
cells to x-irradiation. Thereforewe tried small-dose TBI in lieu of our ini-
tially proposed total-nodal x-irradiation, because of the patients' total
severe ﬂaccidity. The TBI has been extremely beneﬁcial for 3 of our
later-adult-onset DM/PM patients who were totally-weak, totally-limp,
on ventilators and gastric feeding-tubes, andwere previously unrespon-
sive to all other immunosuppression treatments [121–123]. The
cumulatively-dramatic and long-term improvement of these women
resulted in their being off supportive tubes, walking well, and for one
patient, being able to drive on her power-mower. Those TBI treatments
were suggested and carefully supervised by Dr. Alan Lichter [122,123].
They were 15 rads twice-weekly given for 5-weeks, a total course of
150 rads. Thus it seems possible that in some dysimmune patients TBI
might result in a “cure”, especially in elderly patients.
20.7.1 In the immediate future, TBI or a variation of it deserves great-
er consideration for treating dysimmune diseases – that would involve
coordination between a knowledgeable and enthusiastic radiotherapist
and the neuromuscular physician. One of our unproven ideas is “focused
extracorporeal low-level irradiation of shunted circulating blood”, to try
safely to preferentially destroy toxic lymphocytes.
20.8. Interferon-alpha2a (INF-alpha2a): a “cure” for fever-responsive
dysimmune dysschwannian neuropathy?
In one patient this treatment seems to have resulted in an actual
“cure”. The patient is not elderly, but his very successfulN-of-1+ 1 ben-
eﬁt evokes a principle potentially applicable to patients of any age. Pre-
viously, we used Poly-ICLC, an interferon-inducer, each dose of which
caused a 12-hour fever as a side-effect. It was cumulatively extremely
beneﬁcial in an unusual disorder we call “fever-responsive dysimmune
neuropathy” (FRDN). Our ﬁrst FRDN patient, initially quadriparetic and
wheelchair-bound, had had typical 1-3 weeks of slight improvement
following each spontaneous fever) [124]. With our weekly Poly-ICLC-
induced fevers, he had slight and gradually summating regain of very
good strength, and left the wheelchair far behind.
The second FRDNpatientwas a 16-year-old boy (in 11/89)whohad a
previously-untreatable motor dysschwannian polyneuropathy, which
gradually progressed into severe, totally-quadriplegic areﬂexic paralysis
for 2 years – vital capacity was reduced to 1.5 liters (normal 4.5), CSF
protein 56 (upper-normal 45); a limb-muscle biopsy showed promi-
nent muscle-ﬁber atrophy. Our solo treatment agent [125] was self-
administered newly-available Inf-alpha2a subcutsneously, 12×106-units
2×/wk. It was used because it also produces a 12-hr. fever after each
dose. Inf-alpha2a was given for 14-years and slowly produced
cumulatively-dramatic improvement beginning, barely-detectably, the
day following the ﬁrst dose, and more evident 2-3 days later. The
rapid-improvement phase was presumably based on an improved
moment-to-moment molecular function of schwann cells and motor-
neuronal axons . All cumulative beneﬁt achieved has been continuing
undiminished for 11 years after stopping the Inf-alpha2a (with only
some unchanged residual distal weakness) [125]. Currently, he vigor-
ously mountain-bikes, ocean-kayaks, and river-canoes. We propose
that his putatively-pathogenic dysimmune lymphocytes have been ir-
revocably destroyed or have petered out. If so, this may be a “cure” of
his dysimmune disease.
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alpha2 was, in principle, similar to a component of the effect Wagner-
Jauregg was creating by his 1927 Nobel-Prize-winning malaria fever-
therapy for syphilitic “General Paresis of the Insane” a chronic lymphocytic
meningovascularencephalitis.
20.8.1. Pathogenesis implication of interferon beneﬁt – interferon has both
anti-dysimmune and anti-viral actions
Some dysimmune diseases are known (and most are suspected) to
be caused by a persistent immune reaction to a viral, bacterial or other
infection (e.g.myasthenia gravis, HTLV1, v.i.).
The excellent improvement of this FRDN patient suggests that per-
haps: a) Infa2a, or a similarly-acting interferon, merits further consider-
ation for treating dysimmune diseases; and b) we should always treat
dysimmune patients by combining anti-dysimmune and anti-viral (or
other anti-microbial) drugs, or one drug that does both. This concept
is a possible model for future “combined anti-dysimmune plus anti-
microbial therapy”. And in each dysimmune patient perhaps we should
consider searching for tracks of a “relevant possibly-initiating microbe”,
remembering that the initiated dysimmune troublemight have become
cytologically anonymous and autonomous. Probably we all have more
exposure than we realize to our individual occult cargos of viruses.
20.8.1.1. Probably relevant examples.
a) HTLV1 viral myelopathy is at least partly dysimmune, v.i. [39].
b) Occult oncornavirus. Previously, we morphologically identiﬁed viral-
type particles in “normal” chick embryo tissue-cultured muscle, pre-
sumably indicating occult oncornavirus [126]. Possibly it was Rous
sarcoma virus, which is considered to be widely present in chickens.
We propose that that putative endogenous virus explains why
explanted primary cultures of chick-embryomuscle grow so readily
compared to cultured adult human muscle. [Askanas V,Engel WK,
unpublished]. Speculatively, that putatively salutary oncornavirus
releases myo-proliferative and myo-sustaining factors that could
help counteract muscle atrophy of ageing (MAA).
20.9. Adult-onset rod disease, dysimmune (AORDD)
In AORDD, we previously showed an associated IgG monoclonal
gammopathy in two patients [101], and now also in a very-recent third
patient (supervised by S. Mahajan). Recently, we have found AORDD
to be treatable with IVIG, and even more effectively when Rituximab
was added [101]. That third AORDD rod-myopathy patient had, in his
muscle biopsy, in addition to numerous myoﬁbers each containing nu-
merous rods (Fig. 3G), many prominent increase-decrease, pale-center,
and one-way-streak ﬁbers (Fig. 3E,F, each indicative of a) disturbed
structural relationship between mitochondria and myoﬁbrils, and
b) possibly disturbance of the mitochondria themselves (Mahajan and
Engel, unpublished). All 3 of our AORDD patients are men. In the con-
genital and infantile forms of rod (“nemaline”) myopathy (originally dis-
covered with the E-trichrome stain [4,127,128]) several genetic
defects are now known [129–131], but as yet no treatment is available.
For the adult-onset rod myopathy, no gene abnormality has been
described.
Because several adult-onset patient examples (including our 3
patients) had a monoclonal gammopathy and the one so far we have
treated responded well to IVIG + rituximab [101], in this AORDD a
circulating noxious IgGmay be causing dysimmune damage to muscle ﬁ-
bers trans-plasmalemmaly, by an unknown mechanism.
Of possible relevance is that typical rods inmuscle ﬁberswere exper-
imentally produced by tenotomy of cat muscle [18]. In all the human and
cat muscle, the rods are composed of tightly-aggregated protein
molecules.
20.10. Dysimmune multi-microcramps, sometimes called syndrome
of continuous motor-unit activity, also called neuromyotonia, has morerecently been called “generalized multi-microcramps” (MMC's) (v.s.)
[39,132]. Before IVIG was available, immunosuppression treatment
with prednisone, oral cyclophosphamide, and plasmaphereses of a
76-year-old woman, severely-disabled by chronic “continuous
motor-unit activity”, produced essentially-full functional recovery
(regained ability to walk, write, and drive her car). Her excellent re-
sponse provided our ﬁrst indication that her syndrome is an autoim-
mune disease [133].20.9.1. We subsequently proposed that multi-microcramps are somewhat
similar to macrocramps
The discomfort and pain of MMC's are produced by unstable irregular
ﬁring of multiple distal axonal twigs of individual LMNs, each activating
and cramping of perhaps 10-30% of the myoﬁbers it controls. [16,39,
132]. Now, we ﬁnd in many patients that with IVIG treatment the
MMC's often seem to achieve well-repaired molecular healing of the ab-
normal schwann cells and labile neuronal axons. Untreated, the “migrat-
ing” diffuse muscle pain symptoms can produce restlessness and painful
insomnia. The MMC symptoms are often symptomatically rather well-
controlled by modest doses of clonazepam, but that does not produce
the presumed more basic molecular improvement of the abnormal un-
stable neuronal axons achievable with IVIG [16,132].
20.11. Iatrogenic viral HTLV1, with severe subacute progressive spastic
paralysis, and somemuscle fasciculations and cramps;walking regained by
anti-dysimmune therapy. Two men, age 68 and 70, had had a coronary-
bypass procedure, each involving many units of transfused blood. A
few months thereafter, each developed subacute spastic lower-limb pa-
ralysis. Because their culture-negative CSF had elevated lymphocytes
(28 and 111, normal b5), elvated protein 86 and 254 (normal b46),
and elevated IgG synthesis, we started anti-dysimmune treatment,
consisting of prednisone plus oral cyclophosphamide (2 mg/kg/d) in one,
and prednisone plus total-body irradiation (v.s.) in the other. Both had re-
markably improvedwalking, and no longerwerewheelchair dependent
[134]. Treatment was done before routine testing for HTLV1 virus in
donor-blood. Their diagnosis of HTLV1 was prompted by the American
Red Cross' careful look-backmonitoring, which identiﬁed in one patient
the probable source of HTLV1 infection – he had been given blood from
a donor who subsequently, by the then-routine testing, was found to be
HTLV1-positive. After that linkwith one of our patients, the clinical sim-
ilarity of our other patient prompted checking his blood-donors, one of
whomwas that sameHTLV1-positive donor. This is an example of prob-
able “virogenic dysimmunemyelopathy”. Hadwe known of theHTLV1 vi-
remia beforehand, we would have been hesitant to give those anti-
dysimmune treatments. However, our very successful experience en-
courages consideration for similar treatment of HTLV1 myelopathy of
other patients, and it re-emphasizes the likelihood of a virogenic aspect
of various dysimmune diseases (also see Interferon-α2a).
It also supports our concept of considering anti-viral co-treatment
with all anti-dysimmune therapies.20.10. Remote neuromuscular effects of a neoplasm
Some aspects of the pathogenicmechanism(s) for the remote effects
have been suggested to involve i) a dysimmune mechanism, and/or ii)
toxic cytokines and other circulating tumor-released or tumor-
provoked cytotoxins (v.s.). Dysimmune remote effects of a neoplasm
are discussed above. Treatment of the neoplasm itself often does not im-
prove the neuromuscular remote effect. Type-2/2B ﬁber atrophy as a re-
mote effect does not have a successful treatment.Conﬂict of interest
The author has no conﬂict of interest.
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